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Human granulocyte colony-stimulating factor (hG-CSF) is a kind of cytokine and 
produced by primary bone marrow stromal cells, macrophages, fibroblasts and 
endothelial cells. It controls proliferation of granulocyte-monocyte progenitor cells, 
promotes their differentiation and maturation into functionally mature neutrophils which 
are the single most important cellular defense mechanism against bacterial and fungal 
infections. Besides, hG-CSF can also stimulate the release of neutrophils into the 
peripheral circulation, and increase their functional capacity and prolong their survival. 
hG-CSF is a 19.6kDa glycoprotein with 0-glycosylation but no N-glycosylation. 
The function of the sugar chain is still unknown. However, hG-CSF has already been 
produced as non-glycosylated or glycosylated recombinant products in different 
expression systems such as bacteria, yeast，animal cell lines and transgenic animals with 
its in vitro and in vivo biological activities similar to those of the native glycosylated 
hG-CSF. 
Human G-CSF is very useful in clinical applications. It can mainly prevent the 
chemotherapy-induced neutropenia and thus reduce the fatal risk of bacterial and fungal 
infections in patients receiving cytotoxic chemotherapy as the neutrophil count is 
increased by intravenously or subcutaneously injection of recombinant hG-CSF. Besides, 
vii 
rhG-CSF produces significant reductions in hospitalisation costs and in the cost 
associated with antibiotic therapy. Therefore, rhG-CSF has a very high economic value 
and is worth expressing in plants, which would reduce product costs. 
In this study, the main objective is to find whether hG-CSF cDNA can be expressed 
in plants for the production of biologically active recombinant hG-CSF. Three hG-CSF 
chimeric genes were constructed under the control of the phaseolin promoter, which is a 
strong and seed-specific promoter from the phaseolin gene of French bean. These 
constructs were then used to transform tobacco and Arabidopsis using 
Agrobacterium-mQdiatQd transformation. 
Transgenic plants were identified by kanamycin selection and the expression of the 
chimeric genes was assayed. Southern blot analysis showed that the transgene was 
successfully integrated into the genome of transgenic tobacco and Arabidopsis. Besides, 
successful expression of the transgene at mRNA level in both transgenic plants was 
determined by northern blot analysis. Western blot analysis indicated that the 
recombinant hG-CSF was successfully produced in the seeds of transgenic tobacco and 
Arabidopsis. Finally, functional assay using murine myeloblastic cell line NFS-60 and 
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Chapter 1: General Introduction 
Cytokines can be classified as growth factors, lymphokines, colony stimulating 
factors, transforming growth factors, tumor necrosis factors and interferons (Clemens, 
1991). Human granulocyte colony-stimulating factor (hG-CSF) is one of the colony 
stimulating factors (CSFs) or hematopoietic growth factors. This factor is produced by 
primary bone marrow stromal cells, macrophages, fibroblasts and endothelial cells 
(Metcalf and Nicola, 1985; Broudy et al., 1987; Kaushansky et al； 1988; Vellenga et al, 
1988). Unlike other hematopoietic growth factors, hG-CSF is specific for neutrophil 
lineage, where neutrophil is an important cellular defense mechanism against invading 
bacteria and other microorganisms (Palmblad, 1984). Besides, hG-CSF can prolong the 
neutrophil survival (Williams et al., 1990), increase their functional capacity (Kitagawa 
et al., 1987; Yuo et al” 1989, 1990), and stimulate the neutrophil mobilization from 
bone marrow into blood and tissues (Hattori et al.，1996). 
hG-CSF is a 19.6kDa glycoprotein with 0-glycosylation only. The function of the 
carbohydrate chain is still unknown (Oheda et al., 1988). However, hG-CSF has already 
been produced as non-glycosylated recombinant proteins in bacteria and widely used in 
clinical applications as its in vitro and in vivo biological activities are similar to those of 
the native glycosylated hG-CSF (Wingfield et al., 1988; Tanaka and Kaneko, 1992; 
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Tanakaera/., 1997; Hoglund, 1998). 
Due to the specific functions of hG-CSF, it is very useful in clinical applications. 
The major function of hG-CSF is to prevent the chemotherapy-induced neutropenia in 
patients after receiving cytotoxic chemotherapy. By intravenously or subcutaneously 
injection of hG-CSF, the amount of neutrophils increases rapidly so that the recovery 
rate of neutropenia is enhanced and thus the fatal risks of bacterial and fungal infections 
can be largely reduced (Masaoka et al； 1989; Van Der Wouw et al； 1991; Sakata et al., 
1993; Welte et al., 1996). Besides, hG-CSF produces significant reductions in 
hospitalisation costs and in the cost associated with antibiotic therapy (Faulds et al” 
1992; Duncan et al., 1997). Therefore, hG-CSF has a very high economic value. 
As a result, scientists have developed many different expression systems such as 
bacteria, yeasts, animal cell lines and transgenic animals to produce recombinant 
hG-CSF for basic research and clinical use. Moreover，it is very worthwhile to 
expressing this protein in plant system, which has a lower product cost than the other 
expression systems. 
In this study, hG-CSF chimeric genes were constructed under the control of 
phaseolin promoter, which is a strong and seed-specific promoter from the phaseolin 
gene of French bean. These chimeric genes were then used to transform tobacco 
(Nicotiana tabacum L. cv Xanthin. Nc) and Arabidopsis thaliana using 
2 
Agrobacterium-mQ6idiiQ& transformation for the transgene expression in the transgenic 
seeds. The objective is to determine whether the hG-CSF cDNA can be expressed in 
plants and the ultimate goal is to use plants as bioreactors for the mass production of 
rhG-CSF at lower cost to fulfill the high demand for clinical applications. 
3 
Chapter 2: Literature Review 
2.1 Human granulocyte colony-stimulating factor (hG-CSF) 
2.1.1 Physiological roles 
The origins of cytokine research can be traced to the 1950s，and after the great 
contributions of scientists in this field for about half a century, many cytokines have 
been identified and classified into several categories. They are growth factors, 
lymphokines, colony stimulating factors, transforming growth factors, tumor necrosis 
factors and interferons (Clemens, 1991). 
In the 1960s, colony stimulating factors (CSFs) were first identified and named due 
to their abilities of supporting the proliferation and differentiation of hematopoietic 
progenitor cells to form colonies in the semi-solid medium (Bradley and Metcalf, 1966). 
Since then, most of CSFs have been purified to homogeneity and subsequently their 
genes have been cloned and sequenced. As CSFs are mainly involved in regulating the 
proliferation and differentiation of various types of hematopoietic cells, they are also 
named as hematopoietic growth factors. 
There are two groups of hematopoietic growth factors. One group consists of the 
factors whose activity is relatively lineage specific; e.g. macrophage colony-stimulating 
factor (M-CSF, or CSF-1) is specific for macrophage lineage, granulocyte 
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colony-stimulating factor (G-CSF) stimulates the production of neutrophil, interleukin-5 
(IL-5, or Eo-CSF) is the specific proliferating factors for eosinophils while 
thrombopoietin (Tpo) and erythropoietin (Epo) give their specific actions on the 
megakaryocyte and erythrocyte lineages, respectively. On the other hand, the second 
group of hematopoietic growth factors has a wider range of activities on the 
multilineage hematopoietic progenitors such as interleukin-3 (IL-3, or multi-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Figure 2-1) (Clark and 
Kamen, 1987; Schneider and Dy, 1999). 
Human granulocyte colony-stimulating factor (hG-CSF) is one of the colony 
stimulating factors (CSFs) or hematopoietic growth factors. It was first purified from a 
human bladder carcinoma cell line 5637 (Welte et al., 1985) and a human squamous 
carcinoma cell line (CHU-2) (Nomura et al., 1986). Both cell lines produce large 
amounts of hG-CSF constitutively. Human G-CSF is produced by primary bone marrow 
stromal cells, macrophages, fibroblasts and endothelial cells, upon various kinds of 
stimulations such as infections and inflammations. (Metcalf and Nicola, 1985; Broudy 
et al., 1987; Kaushansky et al., 1988; Vellenga et al., 1988). As mentioned before and 
shown in Figure 2-1, hG-CSF can specifically stimulate the proliferation and 
differentiation of CFU-GM (colony forming imits-granulocyte/monocyte) and CFU-G 
(granulocyte) into mature neutrophil, which is one kind of white blood cells or 
5 
leukocytes, and protect our bodies by ingestion and killing of invading bacteria and 
other microorganisms (Palmblad, 1984). However, the half-life of neutrophil is short so 
that hG-CSF plays an essential role in both maintaining a basal level of neutrophils in 
our bodies and greatly increasing their amounts during infection by regulating the 
production of neutrophils from pluripotent stem cells in the bone marrow. Besides, 
hG-CSF can prolong the neutrophil survival (Williams et al., 1990), increase their 
functional capacity (Kitagawa et al., 1987; Yuo et al., 1989, 1990), and stimulate the 
neutrophil mobilization from bone marrow into blood and tissues (Hattori et al., 1996). 
Therefore, hG-CSF plays an important role in protecting our bodies from bacterial, 
fungal and viral infections by regulating the production of mature and functional 
neutrophils. 
6 
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Figure 2-1: Interactions of hematopoietic growth factors in hematopoiesis 
G-CSF (granulocyte colony-stimulating factor) can give a specific action 
on the proliferation and differentiation of CFU-GM (colony forming 
units-granulocyte/monocyte) and CFU-G (granulocyte) to neutrophil 
(bold) while IL-3 and GM-CSF have a wider range of activities on the 
multilineage hematopoietic progenitors. 
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2.1.2 Molecular properties 
Based on the amino acid sequence of hG-CSF purified from a human bladder 
carcinoma cell line 5637 and a human squamous carcinoma cell line (CHU-2) (Welte et 
al, 1985; Nomura et al., 1986), hG-CSF cDNA clones were isolated from the cDNA 
library of CHU-2 and 5637 cell lines, respectively, by using the oligonucleotide probes 
(Nagata et al., 1986a; Souza et al.’ 1986). Then within the same year, the gene for 
hG-CSF was also cloned by Nagata et al. (1986b) from a human gene library. The 
hG-CSF gene is about 2.5kb, and comprises five exons and four introns. Due to there 
are two 5' splice donor sequences, separated by only nine bases，in the second intron of 
the hG-CSF gene, two mRNAs (G-CSFa and G-CSFb mRNA) are generated by 
alternative splicing with G-CSFb mRNA has an elimination of three amino acids at 
position 36-38. According to Nagata et al. (1986a，b), G-CSFb has greater biological 
activity than G-CSFa which has three amino acids more. In addition, scientists found 
that hG-CSF gene is a single gene and localized on chromosome 17q21 by somatic cell 
hybridization studies and chromosomal in situ hybridization (Tweardy et al., 1987). The 
expression of hG-CSF gene is regulated transcriptionally by three regulatory elements 
(G-CSF promoter elements GPEl, GPE2 and GPE3) in a region about 300 nucleotides 
upstream of the ATG initiation codon (Nishizawa et al., 1990). On the other hand, the 
gene can be post-transcriptionally regulated due to the presence of several 
8 
destabilization sequences AUUUA in the 3，untranslated region of G-CSF mRNA 
(Shaw and Kamen, 1986). 
2.1.3 Biochemical properties 
The hG-CSF protein (hG-CSFb) has 204 amino acids including a 30-amino-acid 
signal peptide. The molecular weight of the mature protein without signal peptide is 
18.6kDa. In addition, 0-glycosylation occurs at Thr-133 of the mature protein while 
N-glycosylation does not occur due to the absence of asparagine in the protein. The 
structure of the carbohydrate chain is N-acetyl-neuramic acid a(2-6)[galactose, a(l-3)] 
N-acetylgalactosamine and the molecular weight of the carbohydrate chain is about 
IkDa so that a 19.6kDa hG-CSF glycoprotein is formed (Oheda et al； 1988). The 
function of the carbohydrate chain is still unknown and there is no obvious difference in 
the biological activity between the non-glycosylated recombinant hG-CSF produced in 
E.coli. and native glycocylated hG-CSF (Wingfield et al., 1988; Tanaka and Kaneko, 
1992; Tanaka et al； 1997; Hoglund, 1998). Although Oheda et al (1990) showed that 
the carbohydrate chain had a potential to increase the stability of the hG-CSF protein by 
preventing its polymerization and conformational alterations due to the changes of pH, 
temperature and physiochemical environment. There are five cysteine residues in the 
hG-CSF protein. Except of Cys-17, disulphide bonds are formed between Cys-36 and 
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Cys-42, and between Cys-64 and Cys-74 for a proper folding of the protein (Wingfield 
et al., 1988; Lu et al., 1989). According to Lovejoy et al. (1993) and Zink et al (1994), 
hG-CSF has an antiparallel four-a-helical bundle structure with up-up-down-down 
connectivity. Besides, Reidhaar-Olson et al. (1996) indicated that the N-terminal and 
C-terminal portions of hG-CSF are essential for its binding to hG-CSF receptor. 
2.1.4 Comparison to G-CSF of other species 
Apart from human G-CSF, the cDNAs of murine, bovine, canine and ovine G-CSF 
have also been cloned (Tsuchiya et al., 1986; Lovejoy et al., 1993; O'Brien et al, 1993). 
The nucleotide and amino acid sequence of G-CSFs from different species are quite 
similar to those of human G-CSF with about 70% homology. Their molecular weights 
are also about 20kDa, and the structure of human, bovine and canine G-CSF is similar 
to each other with an antiparallel four-a-helical bundle. Apart from these similarities 
between human G-CSF and those of other species, the most important aspect is that 
their G-CSF activities fully crossreact. However, there are still some differences among 
the G-CSFs. One is that the ovine G-CSF cDNA does not contain sequence of signal 
peptide and the signal peptide of bovine G-CSF is 21 amino acids long, which is nine 
a.a. shorter than human G-CSF. 
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2.1.5 Clinical applications 
Due to the specific role of hG-CSF on the neutrophil lineage in hematopoiesis, this 
protein has been highly regarded as a potential therapeutic agent in the mid 1980s. 
Many preclinical animal studies were performed by injecting hG-CSF to mice, hamsters 
and monkeys with or without chemical treatment. In the normal animals, the number of 
neutrophils increased from five to ten folds within 24 hours after injection. On the other 
hand, the period of chemotherapeutically induced neutropenia was shortened and the 
infection-associated morbidity and mortality of neutropenia was reduced in the animals 
after chemical treatment. Besides, the hG-CSF activity was specific to neutrophil 
lineage only while no considerable changes were observed in other hematopoietic 
lineages (Cohen et al., 1987; Tsuchiya et al., 1987; Welte et aL, 1987; Ono et al, 1988). 
Extensive clinical studies (Phase I / II / III) had been performed and the results 
showed that the therapeutic potential uses of hG-CSF were high in many treatments. 
The major function of hG-CSF in clinical applications is to hasten the neutrophil 
recovery in patients due to the neutropenia from various causes and as a result, reduce 
the fatal risks of bacterial and fungal infections. Neutropenia can be divided into 
acquired and congenital neutropenia. Acquired neutropenia is mainly caused by 
induction of chemotherapy and radiotherapy for cancer treatments, immuosuppressive 
agents after organ transplantation, both autologous and allogeneic bone marrow 
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transplantation, acute leukemia and acquired immune deficiency syndrome (AIDS). 
After hG-CSF treatment, patients with these acquired neutropenias had accelerated 
recovery of neutrophils and the incidences of lethal infections were decreased (Masaoka 
et al., 1989; Van Der Wouw et al., 1991; Sakata et al., 1993; Welte et al., 1996). On the 
other hand, positive results were also observed in treatments of naturally occurring 
neutropenia including cyclic neutropenia and severe congenital neutropenia (Hammone 
et al,, 1989; Welte et al., 1990). Besides, administration of hG-CSF can mobilize 
hematopoietic progenitor cells from bone marrow to the peripheral blood so that instead 
of bone marrow, blood cells can be harvested for autologous transplantation (Winter et 
al,, 1996). Moreover, gene therapy using hG-CSF as a target gene may be a therapeutic 
choice for the treatment of neutropenic patients in future by delivering stable levels of 
neutrophils. According to Moisset et al. (2000), gene therapy was performed in 
nonhuman primates by injection of genetically modified myoblasts, which can produce 
hG-CSF into Macaca mulatta. The result showed that hG-CSF was produced in the 
animals and the level of neutrophils increased from four to five folds although their 
concentrations decreased over time. 
In 1991，the Food and Drug Administration (FDA) of the United States 
approved hG-CSF as a drug (Murakami and Nagata，1998). The dose of hG-CSF 
applied to the patients is in the range from 1 to 60 |Lig/kg/day (median dose: 5 jig/kg/day) 
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and the applied method is intravenously or subcutaneously injection (Herrmann et al； 
1992). Patients will be given hG-CSF daily for 10 to 14 days，beginning one to two days 
after cancer-related chemotherapy treatments. The side effect of hG-CSF therapy is 
relatively little. The most common one is mild to moderate bone pain which can be 
controlled with acetaminophen (Morstyn et al., 1989) and only several cases of 
cutaneous vasculitis were reported (Jain, 1994). However, hG-CSF can also stimulate 
the proliferation and growth of some tumor cells only without differentiation (Vellenga 
et al., 1987; Begley et al., 1988). Therefore, caution must be taken carefully when 
hG-CSF therapy is applied to cancer patients. 
2.1.6 Economic value 
Nowadays, cancer is one of the most common diseases in the world and many new 
cases are diagnosed each year. Chemotherapy and radiotherapy are commonly used in 
cancer treatments. However, both therapies can cause a very adverse side effect ~ 
neutropenia in patients and consequently increase the incidence of bacterial, flingal and 
viral infections. In 2001, about 1.4 million patients received chemotherapy and 1.27 
million new cancer cases were diagnosed in the United States. Therefore, administration 
of hG-CSF that can reduce the duration of neutropenia and risks of various infections is 
a great benefit to many cancer patients after chemotherapy and radiotherapy. Moreover, 
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hG-CSF also plays an essential role in treatment of neutropenia from other diseases and 
mobilization of hematopoietic stem cells as described in section 2.1.5. As a result, there 
is a very high demand of hG-CSF in clinical applications all over the world. 
In 1991, Amgen, a global biotechnology company, first manufactured and 
marketed recombinant hG-CSF, NEUPOGEN® (generic name: filgrastim) which is 
produced from E. coli and was approved as a drug by the US FDA in the same year. 
According to the Amgen reports forth quarter and full year 2001 financial results in line 
with guidance, worldwide sales of NEUPOGEN® were US $1.3 billion for the full year 
2001 with 10% annual increases compared to that in the prior year (US $1.2 billion). 
Meanwhile, the overall sales of rhG-CSF in all pharmaceutical companies were over 
US $2 billion in 2000. Nowadays, rhG-CSF is one of the top-selling pharmaceutical 
proteins and the best selling product in anti-cancer drug market. 
Besides, hG-CSF therapy can in turn reduce the duration of hospitalization (25.3 
days V5" 29.8 days) and antibiotic therapy (14.5 days v^  18.6 days) with subsequent cost 
benefits to both hospitals and patients (Faulds et al., 1992; Duncan et al., 1997). Due to 
these important and beneficial factors, the economic value of hG-SCF is very high and 
it is worth to producing this pharmaceutical protein in large scale for clinical use. 
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2.2 Expression systems producing recombinant hG-CSF 
After the cloning of hG-CSF cDNA (Nagata et al., 1986a; Souza et al., 1986), 
large amounts of recombinant hG-CSF (rhG-CSF) were produced in bacteria, yeasts, 
animal cell lines and transgenic animals for basic research and clinical use. 
2.2.1 Bacteria 
Recombinant hG-CSF was first expressed in Escherichia coli under the control of 
the cPl promoter by Souza et al. (1986). Then many successful cases were obtained in 
the following years. Komatsu et al. (1987) showed that a high level of rhG-CSF (about 
10% of total cellular proteins) was produced in E. coli under the control of the trp 
promoter and Wingfield et al. (1988) obtained a 20% recovery of pure rhG-CSF from 
wet cells using E. coli strain W3110. Although cysteine bridges can be formed in E. coli, 
it is very difficult to get proper folding to the correct three-dimensional structure of the 
recombinant protein. Therefore, the proteins produced from E. coli are required to 
undergo in vitro or in vivo renaturation that in turn increases the cost of downstream 
processing. Besides, the recombinant proteins are non-glycosylated. However, this is 
not a problem because the in vitro and in vivo biological activities of non-glycosylated 
rhG-CSF produced in E. coli were similar to those of native hG-CSF and glycosylated 
rhG-CSF produced in animal cell lines (Wingfield et al., 1988; Tanaka and Kaneko, 
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1992; Tanaka et al., 1997; Hoglund, 1998). This kind of non-glycosylated rhG-CSF has 
been widely used in clinics and named as filgrastim. 
As E. coli is one of the major expression systems in producing rhG-CSF for 
clinical applications, scientists have tried to improve the yield and quality of rhG-CSF 
by various methods. Yamasaki et al. (1994, 1998) enhanced the stability of rhG-CSF by 
binding polyethylene glycol (PEG) to the proteins and by using various rhG-CSF 
derivatives such as KW-2228 with five amino acid substitutions in order to decrease the 
plasma clearance rate and consequently a more effective hematopoiesis could be 
achieved. On the other hand, Chung et al. (1998) tried to increase the yield of rhG-CSF 
by fusing the gene encoding mature hG-CSF with the pectate lyase B (pelB) signal 
peptide of Erwinia caratovora. The result showed that high level (1.7g/l) of the fusion 
protein, pelB-hG-CSF, was produced in an inclusion body form although there was no 
signal peptide processing and rhG-CSF secretion. However, Jeong and Lee (2001) 
demonstrated that insertion of the histidine hexamer and factor Xa cleavage site (a small 
oligopeptide - 13 amino acids) between the Bacillus sp. endoxylanase signal peptide 
and the mature hG-CSF protein allowed successful secretion of rhG-CSF into the 
periplasmic space of E. coli. Moreover, the production level of rhG-CSF was high 
(20-22% of total proteins) and the secretion efficiency was greater than 98%. 
In addition，plasmid stability is very important for long-term rhG-CSF production 
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in E. coli. According to Choi et al. (2000)，the plasmid using the L-arabinose promoter 
system of E. coli was much more stable in the flask relay culture (>100 generations) 
than in the cyclic fed-batch culture 4 generations). The possible reasons were the 
relatively high-cell density and high-level expression of rhG-CSF in the cyclic fed-batch 
culture, which in turn caused the segregational plasmid instability. 
2.2.2 Yeasts 
Yeast is another expression system for production of rhG-CSF. It is easy to 
scale-up and the culture medium is simple and inexpensive. Moreover, yeast has 
abilities for eukaryotic modification and processing. Therefore, the recombinant protein 
is glycosylated and correctly folded. However, some unforeseen problems such as low 
yield (compared to that in bacteria), low secretion efficiency, instability of high-copy 
vectors and hyperglycosylation are encountered (Ratner, 1989; Pen, 1996). 
According to Yang et al. (1997), the production level of rhG-CSF with the 
intracellular KEX2 cleavage site in Saccharomyces cerevisiae was more than 60mg/l 
while the cell concentration was 70g/l. However, the expression level was not high 
enough and as a result, Bae et al. (1998) and Lee et al. (1999) invented a novel 
secretion system of recombinant Saccharomyces cerevisiae by using a hybrid fusion 
peptide to enhance the secretion of rhG-CSF at high cell concentration. The expression 
17 
cassette consisted of the inducible UASgal/MF-alpha 1 promoter, killer toxin signal 
peptide, amino acids Ser5-Ala28 of human mature interleukin-1 -beta, the KEX2 dibasic 
endopeptidase cleavage site, and hG-CSF. The results showed that a core 
N-glycosylation at the N-terminus fusion of hIL-l-beta played a critical role in 
enhancing the secretion of rhG-CSF to the culture medium. However, the secreted 
rhG-CSF was observed to exist as large multimers. This problem was then overcome by 
Bae, et al. (1999). They added Tween 80，a non-ionic surfactant, to the culture medium 
for preventing the secreted rhG-CSF from multimerization and increased the culture pH 
to 6.5 for improving the monomer fraction and secretion efficiency so that the secreted 
monomer was purified with high recovery yield up to 47%. 
2.2.3 Animal cell lines 
Animal cell line is another promising expression system for production of rhG-CSF. 
The recombinant proteins were first produced in monkey COS cells by Nagata et al. 
(1986). Then mouse CI271 cells and Chinese hamster ovary (CHO) cells were 
transformed to produce high levels of rhG-CSF in the range from 10 to 40mg/l although 
this production level was lower than that in bacteria (Tsuchiya et al., 1987; Kubota et al” 
1990). The recombinant proteins were glycosylated and identical with the biochemical, 
structural and biological properties of native hG-CSF. This glycosylated form of 
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rhG-CSF was also widely used in clinic applications and named as lenograstim. 
However, there are still some drawbacks in mammalian cell production system 
such as high upstream costs because of the requirement for expensive fetal bovine 
serum in the growth medium, relatively low-yielding and high risk of human pathogens 
contamination (Pen, 1996). Besides, cultured mammalian cells are sensitive to shear 
forces that occur during industrial-scale culture, and to variations in temperature, pH, 
dissolved oxygen, and certain metabolites. Therefore, culture conditions must be 
controlled carefully; otherwise the fermentation and product purity would be affected by 
the variation in cell growth (Giddings et al., 2000). 
2.2.4 Transgenic animals 
Different from transformed bacteria, yeasts and animal cell lines producing large 
amounts of rhG-CSF for clinical use, Yamada et al. (1996) and Serizawa et al. (2000) 
made use of mice transgenic for hG-CSF as an experimental model to further 
investigate the biological functions of hG-CSF in the regulatory mechanism of 
hematopoiesis and the possible adverse consequences of persistent neutrophil 
overproduction in patients with long-term injection of rhG-CSF. The results showed that 
granulocytosis was observed as expected and lymphocytosis even occurred when 
rhG-CSF was expressed in a certain condition in transgenic mice, indicating a more 
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potential physiological roles of hG-CSF than expected. Moreover, neutrophilia induced 
by rhG-CSF alone was insufficient to cause adverse effects in transgenic mice while 
factors other than long-term overexpression of rhG-CSF and more extensive 
neutrophilia were required for the development of neutrophil-mediated tissue injury. 
2.2.5 Transgenic plants 
Apart from bacteria, yeasts, animal cell lines and transgenic animals, plant is a 
novel and promising production system for recombinant proteins in the recent years. 
However, no published reports on the expression of hG-CSF in transgenic plants are 
available thus far although some scientists have transformed plants or plant cells to 
produce other hematopoietic growth factors, such as granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and erythropoietin (Epo). This will be discussed 
later in more detail. 
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2.3 Plant as bioreactors 
Due to the rapid developments of plant molecular biology and biotechnology, it is 
now possible to use plants as bioreactors to produce biomolecules and heterologous 
proteins，such as lipids, carbohydrates, industrial enzymes and pharmaceutical proteins 
(Goddijn and Pen, 1995). Although biotechnology companies have commonly used 
bacteria, yeasts and animal cells rather than plants for production of industrial and 
pharmaceutical proteins in the markets, the commercial potential of using transgenic 
plants as production system is very high due to the unique and outstanding 
characteristics of the plants. Nowadays, several biotechnology companies are 
enthusiastically developing, field testing, and patenting plant expression systems 
(Giddings et al., 2000). In Canada, SemBioSys (Calgary, Canada) has produced hirudin, 
an anticoagulant used to treat thrombosis, from transgenic oilseed rape commercially 
for the first time (Boothe et al., 1997). Besides, the very high feasibility of 
technological improvements in transgenic plants, compared to the traditional 
fermentation-based production systems, can also allow these novel plant bioreactors to 
reach the market place (Pen, 1996). 
21 
2.3.1 Characteristics of using plant as bioreactors 
First of all, plant production systems are more economical compared to the 
fermentation-based production systems. The production cost of transgenic plants is low, 
as plants only require water, soil, sunlight and some fertilizers for efficient growth while 
huge capital investments such as expensive fermenters, equipments and medium are 
needed in the fermentation-based production system (Goddijn and Pen, 1995). 
Moreover, for transgenic plants, the process of upscaling is simple, fast and inexpensive 
while upscaling in fermentation-based production is complex, time-consuming and 
expensive. According to Kusnadi et al. (1997), the cost of producing recombinant 
proteins in plants has been estimated to be 10- to 50-fold lower than that in E. coli 
fermentation. Moreover, plant production systems can offer a promising potential to 
mass-produce some of the most expensive biopharmaceuticals of restricted availability, 
such as glucocerebrosidase, in a much cheaper way (Giddings et al., 2000). 
In addition, the recombinant products from transgenic plants are free from 
contamination of potential human pathogens such as endotoxins from bacteria，viruses 
and oncogenic DNA from mammalian cells, and prions and viruses from transgenic 
animals (Pen, 1996). 
Furthermore, the transgenic plant products can be easily harvested, transported and 
processed using the well-established technology. The expression of recombinant 
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proteins in seeds under seed-specific promoter can also offer a long-term and 
convenient storage without the need for either cryopreservation or continual 
subculturing. Besides, self-fertilization of the transgenic plants can give rise to a stable 
inheritance of the trait (Whitelam et al., 1993; Goddijn and Pen, 1995). 
Plants have post-translational modifications like other eukaryotic systems. 
However, consideration must be taken when one tries to use transgenic plants to 
produce recombinant glycoproteins where the sugar chain is critical for biological 
activity or stability because the glycosylation of plants is different from that of 
mammals and other eukaryotes although certain features remain common (Goochee et 
al., 1991; Warren, 1993). Moreover, some unique carbohydrate moieties of plants may 
cause an antigenic challenge to the immune system. Therefore, mutant plants lacking 
some of the enzymes involved in the glycosylation pathway have been generated and 
chemical modification of the plant-derived glycoproteins should be carried out after 
isolation (Giddings et al., 2000). 
In conclusion, using transgenic plants as factories for biopharmaceutical proteins 
has many economic and qualitative benefits. However, product purification from 
transgenic plants has proven expensive. Therefore, scientists are currently developing 
various methods to tackle this problem. One method called oleosin-fusion technology, 
which allows extraction with oil bodies, is likely to make purification easier and cheaper. 
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In some cases, biopharmaceuticals can be delivered as edible products by direct 
ingestion of the transgenic seeds, tubers or fruits without any purification (Giddings et 
al., 2000). 
2.3.2 Transgenic plants producing hematopoietic growth factors 
Human GM-CSF and Epo are two members of the human hematopoietic growth 
factors. Both of them are glycoproteins, useful in clinical applications and highly 
demanded all over the world similar to human G-CSF. Therefore, scientists have tried 
hard to establish a plant system for mass production of these pharmaceutical proteins in 
a more economical way. 
2.3.2.1 Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
In 1995，Ganz et al. showed that the cDNA encoding human GM-CSF could be 
successfully expressed in the seeds of transgenic tobacco under the control of the rice 
glutelin promoter, Gt3, and the NOS terminator with the glutelin signal peptide fused to 
the N-terminal end of the GM-CSF transgene. ELISA assay indicated that the 
expression level of GM-CSF in the seeds of transgenic plants was 258ng/ml and 
functional assay revealed that the recombinant human GM-CSF produced in transgenic 
plants had in vitro biological activity by stimulating the growth of GM-C SF-dependent 
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cell line TF-1. 
James et al. (2000) had also used genetically modified tobacco plant cells to 
produce human GM-CSF under the control of the cauliflower mosaic vims (CaMV) 35S 
promoter and the T7 terminator with the tobacco etch vims (TEV) leader sequence 
fused to the 5' end of the mature GM-CSF cDNA. The production levels of extracellular 
and intracellular GM-CSF in the culture were 250 and 150|ig/L, respectively. Moreover, 
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the addition of bovine serum albumin (BSA) and salt to the growth medium could 
increase the recovery of extracellular GM-CSF as a more natural environment for 
GM-CSF as in vivo blood conditions was created. In addition, the recombinant 
GM-CSF was biologically active in vitro as it stimulated the proliferation of murine 
32D cell line, which totally depends on GM-CSF for growth and survival. 
However, the N- and 0-glycosylation states in both cases remain unclear and a 
more detailed biochemical analysis would be required. Moreover, in vivo biological 
activity assay should be carried out to see whether the differences in glycosylation 
between plants and humans would decrease the in vivo stability of recombinant human 
GM-CSF produced in plants although the in vitro biological activity of GM-CSF is not 
affected by the type of glycosylation. 
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2.3.2.2 Erythropoietin (Epo) 
Human Epo is highly glycosylated at three N-glycosylaiton sites and the sugar 
chains occupy about 50% of the molecular weight of the glycoprotein (Jacobs et al., 
1985). According to Matsumoto et al (1993), human Epo cDNA could be expressed in 
tobacco cell cultures under the control of the CaMV 35S RNA promoter and terminator, 
but the yield was very low (Ipg/g of wet cells). Moreover, Matsumoto et al. (1995) 
showed that the N-linked oligosaccharides of recombinant Epo produced in tobacco 
cells were smaller than those produced in mammalian cells. Similar to GM-CSF, the in 
vitro biological activity of recombinant Epo produced in tobacco cells was not affected 
by the type of glycosylation. However, results indicated that the recombinant Epo had 
no in vivo biological activity and the possible reason may be the lack of sialic acid 
residues in the N-linked oligosaccharides of Epo. As a result, the in vivo half-life of 
recombinant Epo was reduced from hours to minutes and easily cleared from the 
circulation before carried out its actions on erythropoietic tissues. 
On the other hand, He et al. (1998) had used leafdisc co-cultivation to transform 
tomato plants for the expression of human Epo cDNA using the CaMV 35S RNA 
promoter and NOS terminator as regulatory sequences. Results showed that the 
production level of recombinant Epo was about 400pg/g of leaf and the proteins were in 
vitro biologically active. However, assay for in vivo biological activity had not been 
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carried out to confirm the stability of the recombinant Epo in vivo. 
Although the two above examples showed that the type of glycosylation may affect 
the in vivo stability of recombinant human GM-CSF and Epo produced in transgenic 
plants and in turn reduce their in vivo biological activities, it should not be the case in 
human G-CSF as the in vitro and in vivo biological activities of non-glycosylated 
rhG-CSF produced in E. coll were similar to those of native hG-CSF and glycosylated 
rhG-CSF produced in animal cell lines (Wingfield et al., 1988; Tanaka and Kaneko, 
1992; Tanaka et al., 1997; Hoglund, 1998). Moreover, this kind of non-glycosylated 
rhG-CSF (filgrastim) has been widely used in clinics. Therefore, it is possible to use 
plants as bioreactors for the production of rhG-CSF with both in vitro and in vivo 
biological activities for clinical applications. 
2.3,3 Arabidopsis and tobacco as model plants 
Methods for introducing transgenes into a full range of plant species are not yet 
well established. Therefore if it is the first time to test whether transgenic plants can be 
utilized to produce a target recombinant product, it is better to use a model plant species 
such as Arabidopsis or tobacco as host although these plants may not be the ultimate 
systems for mass production. This is mainly because much more information of these 
plants is known and their transformation methods are well established. Many successful 
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cases have been reported for these plant production systems (Lloyd et al,, 1986; Robert 
et al., 1989; Pen et al., 1992; Bechtold et al； 1993; Fiedler and Conrad, 1995). 
2.3.3.1 Arabidopsis 
Arabidopsis thaliana is a typical higher plant and belongs to the class Brassicaceae. 
However, its genome size is small and only includes five pairs of chromosomes with 
approximately 140,000 kilobase pairs. As a result, scientists have widely used 
Arabidopsis as model plant in molecular genetics studies and many mutants have been 
identified and studied (Meyerowitz, 1989; Damm et al., 1993). Besides, its short 
generation time, small size, abundant seed production and ability to grow well in 
constant fluorescent light made it suitable for mass production indoor with inexpensive 
and easy maintenance. In addition, due to the short generation time, homozygous line of 
transgenic plants can be quickly obtained by series of self-pollination and selection. 
2.3.3.2 Tobacco 
Tobacco is another model plant in the transgene expression study. Although its size 
is larger than Arabidopsis and the generation time is longer, tobacco is still a good 
candidate for transgenic plant production as tobacco seeds are larger and produced more 
abundantly. As a result, more recombinant products can be harvested from the 
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transgenic tobacco for various assays. Moreover, the larger flowers of tobacco make 
flower tagging more easily during study on the developmental profile of seed protein. 
2.3.4 Phaseolin and its regulatory sequences 
A strong and seed-specific promoter is an essential element in using plants as 
bioreactors as large amounts of recombinant products can be produced and stored in 
seed, which is a very good candidate for long-term storage, harvesting, processing and 
transportation (Pen, 1996). A numbers of seed-specific promoters have been 
characterized including the phaseolin promoter, which is the regulatory sequence of the 
major seed storage protein — phaseolin in French bean {Phaseolin vulgaris L.). 
Phaseolin is a group of polypeptides and accounts for 50% of the total protein in 
mature seeds in French bean (Ma and Bliss, 1978). Phaseolin consists of 3 subunits, a, a 
and a polypeptides with molecular weights of 51, 48 and 45.5kDa, respectively. 
According to Sun et al. (1978), the three polypeptides were encoded by 16S mRNA 
species. Moreover, the study showed that phaseolin starts to accumulate in developing 
cotyledons of 7mm in length and continued until the cotyledons reached 17-19mm 
during embryo development. Sun et al. (1981) first isolated the a-phaseolin gene from 
French bean. The gene consists of 80bp of 5' untranslated region, 1263bp of protein 
encoding region and 135bp of 3’ untranslated region. Later, Bustos et al. (1989) found 
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that the seed and temporal specific expression of phaseolin gene was regulated by the 
cw-acting sequence around the -295 to +20 upstream region of the gene. 
As phaseolin promoter is a strong and seed-specific promoter, it is a good 
candidate for the transgene expression in plants. According to Hoffman et al, (1987), a 
maize 15kDa methionine-rich zein protein under the control of phaseolin promoter was 
produced in the endosperm and embryo tissues of transgenic tobacco seeds up to 1.6% 
of the total seed protein. Moreover, strong expression of cDNA encoding the Brazil nut 
methionine-rich protein (up to 30%) using the phaseolin promoter as regulatory 
sequence in transgenic tobacco and canola seeds were reported by Altenbach et al. 
(1989, 1992). 
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2.4 Plant transformation methods 
2.4.1 Agrobacterium-mtdmitA transformation 
This transformation method using Agrobacterium as agent for DNA delivery into 
the plant genome has been well established and commonly used by scientists for many 
years. Among the different species of Agrobacterium, A. tumefaciens, which cause 
crown gall disease, is the most important one for plant transformation. The principle of 
the method is based on the capability of the plant pathogenic Agrobacterium to excise 
the transfer-DNA (T-DNA) from its tumor-inducing (Ti) plasmid, then transfer the 
T-DNA from bacteria to plant cell and finally integrate the T-DNA into the plant 
genome (Meins et al； 1980; Stachel and Zambryski, 1986; Gelvin，1993). There are two 
types of strategy to generate stable transgenic plants by Agrobacterium-mQdidiXQd 
transformation; one is tissue culture method while the other is non-tissue culture (in 
planta) method. 
2.4.1.1 Tissue culture methods 
This method is based on the co-cultivation of the sterile and morphogenetic plant 
tissues with Agrobacteria for about 24-48 hours so that the T-DNA of Agrobacterium 
can be integrated into the plant genome. Then the bacteria on the plant tissues are killed 
by antibiotics and the whole transgenic plant is regenerated from the transformed plant 
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tissues by growing in different inducing media with suitable selection antibiotics. The 
explant tissue used for co-cultivation can be leaf tissue, root tissue, hypocotyl or 
cotyledons according to the plant species. However, this tissue culture method is only 
suitable for plant species with high regeneration efficiency of the transformed tissue in 
the inducing medium. In 1985，Horsch et al. first used leaf-discs of tobacco as explant 
tissues for co-cultivation with Agrobacteria and the transformation was effective. In 
addition, Lloyd et al. (1986) also carried out this leaf-disc technique to transform 
Arabidopsis with hygromycin resistance gene. Moreover, according to Valvekens et al. 
(1988), Arabidopsis roots could also be used as explants for Agrobacterium-mQdidXQd. 
transformation where the Agrobacterium containing Ti plasmid harboring kanamycin 
and herbicide resistance genes. 
2.4.1.2 Non-tissue culture (In planta) methods 
There are several potential risks involved in the tissue culture method such as 
morphological changes, somatic mutations and infertility among the regenerated 
transgenic plants. Therefore, Feldmann and Marks (1987) first developed a non-tissue 
culture (in planta) method by co-cultivation of Arabidopsis seeds with Agrobacteria 
containing Ti plasmid carrying kanamycin resistance gene during imbibition. The result 
showed that some treated seeds could germinate and grow under kanamycin selection. 
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Then another in planta technique was established by Katavic et al. (1994) in which 
primary and secondary inflorescence were excised and the wound sites were inoculated 
with Agrohacterium. Finally, Bechtold et al. (1993) developed the third in planta 
method by using the vacuum infiltration of the whole Arabidopsis plants in 
Agrohacterium cells suspension. 
2.4.2 Direct DNA uptake transformation 
Due to some plant species especially monocots cannot be efficiently transformed 
by Agrobacterium'mQdL\dXQ& transformation, the method of direct DNA transfer has been 
developed to provide an alternate way for plant transformation. The principle of direct 
DNA uptake system is based on the direct introduction of naked DNA molecule into the 
plant genome without the assistance of Agrohacterium and Ti plasmid-based 
transformation vector. This method, via electrical, chemical or other physical delivery 
mechanisms, will overcome the DNA uptake barriers such as plant cell wall and plasma 
membrane. 
2.4.2.1 Chemical methods 
According to Krens et al. (1982), the chemical polyethylene glycol (PEG) could be 
used to facilitate the direct DNA uptake into the plant protoplasts of both dicots and 
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monocots. Moreover, based on the PEG-mediated direct DNA uptake method, the 
protoplasts of both tobacco and Arabidopsis were successfully transformed by 
incubating with the naked DNA (Negrutiu et al., 1987; Damm et al., 1989). However, 
this chemical method can only be applied to protoplast transformation as the cell wall of 
the intact cells acts as a significant barrier to direct DNA uptake, even the cells are 
treated with PEG. 
2.4.2.2 Electrical methods 
In 1986, Morikawa et al. first developed a new method to introduce the naked 
DNA molecules into the intact cells rather than protoplasts by electroporation. Many 
successful cases were subsequently reported. According to D'Halluin et al. (1992), 
electroporated maize immature embryos were regenerated to transgenic plants after 
inoculation with DNA. Moreover, the production of transgenic sugar cane using tissue 
electroporation was reported by Arencibia et al. (1995). 
2.4.2.3 Physical methods 
Particle bombardment is a commonly used physical method for plant 
transformation. First, the DNA is coated onto a very small metal microspheres of gold 
or tungsten with diameters of l-4|Lim. Then the DNA-coated particles are placed on a 
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macroprojectile, which is accelerated towards the plant tissues by using air pressure 
such as helium, electrostatic pulse or gunpowder percussion. When the accelerated 
macroprojectile strikes to a stopping plate, the DNA-coated particles are propelled 
onwards and passed through the cell wall and plasma membrane into the cells. Finally, 
the DNA is released from the metal particles and expressed transiently or integrated into 
the plant genome. By using this particle bombardment method, many plant species can 
be transformed such as tobacco (Klein et al., 1988), Arabidopsis (Seki et al.’ 1991a,b), 
soybean (McCabe et al., 1988) and rice (Christou et al, 1991). 
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Chapter 3: Materials and Methods 
3.1 Introduction 
In this study, three chimeric gene constructs encoding hG-CSF under the control of 
the French bean seed-specific phaseolin promoter were made. They were then used to 
transform tobacco and Arabidopsis via Agrobacterium-mQdmtQd method. Transgenic 
plants were identified and the expression of the chimeric gene was analyzed by 
molecular, biochemical and functional assays. 
Transgenic plants harboring the first construct (phaseolin promoter + His-tag + 
hG-CSF + phaseolin terminator) without the phaseolin signal peptide are expected to 
have their hG-CSF protein present in the seed cytosol while those containing the second 
construct (phaseolin promoter + phaseolin signal peptide + His-tag + hG-CSF + 
phaseolin terminator) or third construct (phaseolin promoter + phaseolin signal peptide 
+ hG-CSF + phaseolin terminator) with the phaseolin signal peptide are expected to 
have their hG-CSF protein deposited in protein bodies of transgenic seeds. Besides, the 
difference between the last two constructs is that the third construct contains no 5' 
cleavable histidine-tag in order to check whether it would affect the expression of 
hG-CSF in transgenic plants. 
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3.2 Chemicals 
All the chemicals used were reagent grade or molecular grade, and were purchased 
from Sigma Chemical Co. or Bio-Rad Co. (unless otherwise specified). 
3.3 Bacterial strains 
For chimeric gene construction, E. coli DH5 a was used as host for the plasmid 
DNAs. For Arabidopsis transformation, Agrobacterium tumefaciens GV3101/pMP90 
(Koncz and Schell, 1986) was used while for tobacco transformation, A. tumefaciens 
LBA4404/pAL4404 (Hoekema et al., 1983) was used. 
3.4 Chimeric gene construction 
The cDNA clone of human granulocyte colony-stimulating factor (hG-CSF) in 
pB/KS/hG-CSF was obtained from Dr. Wei Han (The Memorial Sloan-Kettering Cancer 
Center). The size of the hG-CSF cDNA is 615bp in length including the 30a.a. hG-CSF 
signal peptide sequence (90bp) and 174a.a. mature peptide sequence (525bp) (Figures 
3-1 and 3-2). In this study, only the mature peptide sequence was cloned and used in 
chimeric gene construction. The first two chimeric genes, with 5' cleavable histidine-tag, 
were made in the presence or the absence of the phaseolin signal peptide while the third 
one was made with phaseolin signal peptide only. The three chimeric genes were then 
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cloned into the Agrobacterium binary vector pBI121 to form the final constructs, which 
were used for Agrobacterium and plant transformation. 
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ATG GCT GGA CCT GCC ACC CAG AGC CCC ATG AAG CTG ATG GCC CTG CAG 
CTG CTG CTG TGG CAC AGT GCA CTC TGG ACA GTG CAG GAA GCC ACC 
CCC CTG GGC CCT GCC AGC TCC CTG CCC CAG AGC TTC CTG CTC AAG 
TGC TTA GAG CAA GTG AGG AAG ATC CAG GGC GAT GGC GCA GCG CTC 
CAG GAG AAG CTG TGT GCC ACC TAG AAG CTG TGC CAC CCC GAG GAG 
CTG GTG CTG CTC GGA CAC TCT CTG GGC ATC CCC TGG GCT CCC CTG 
AGC AGC TGC CCC AGC CAG GCC CTG CAG CTG GCA GGC TGC TTG AGC 
CAA CTC CAT AGC GGC CTT TTC CTC TAG CAG GGG CTC CTG CAG GCC 
CTG GAA GGG ATC TCC CCC GAG TTG GGT CCC ACC TTG GAC ACA CTG 
CAG CTG GAC GTC GCC GAC TTT GCC ACC ACC ATC TGG CAG CAG ATG 
GAA GAA CTG GGA ATG GCC CCT GCC CTG CAG CCC ACC CAG GGT GCC 
ATG CCG GCC TTC GCC TCT GCT TTC CAG CGC CGG GCA GGA GGG GTC 
CTA GTT GCC TCC CAT CTG CAG AGC TTC CTG GAG GTG TCG TAG CGC 
GTT CTA CGC CAC CTT GCC CAG CCC TGA 
Figure 3-1: Nucleotide sequence of hG-CSF cDNA 
The size of hG-CSF cDNA is 615bp in length with the start and stop 
codons (bolded). The hG-CSF signal peptide sequence is 90bp in length 
(underlined) while the mature protein sequence is 525bp. 
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M A G P A T Q S P M K L M A L Q L L L W H S A L W T V Q E A 
T P L G P A S S L P Q S F L L K C L E Q V R K I Q G D G A A 
L Q E K L C A T Y K L C H P E E L V L L G H S L G I P W A P 
L S S C P S Q A L Q L A G C L S Q L H S G L F L Y Q G L L Q 
A L E G I S P E L G P T L D T L Q L D V A D F A T T I W Q Q 
M E E L G M A P A L Q P T Q G A M P A F A S A F Q R R A G G 
V L V A S H L Q S F L E V S Y R V L R H L A Q P Stop 
Figure 3-2: Deduced amino acid sequence of hG-CSF 
The hG-CSF consists of 204 amino acids with 30a.a. signal peptide 
(bolded) and 174a.a. mature peptide. 
Ncol 
5，GCSF-1 ] 5'- GCAGCCATGGCCACCCCCCTGGGCCCT -3' 
Ndel 
5，GCSF-2 ] 5'- CGCCATATGCCACCCCCCTGGGCCCT -3， 
Accl 
3，GCSF 1 5'- GAAGTATACTCAGGGCTGGGCAAGGTGGC -3' 
Figure 3-3: Primers for the amplification of hG-CSF mature peptide sequence 
by PGR 
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3.4.1 Cloning of pTZ/Phas/His/EK/hG-CSF 
The nucleotide sequence (525bp) encoding the hG-CSF mature peptide in 
pB/KS/hG-CSF was first amplified by PGR using two specific primers (Figure 3-3), 
which can introduce a 5' Ncol site and a 3' Accl site to the target gene for sub-cloning. 
A 50|il PGR reaction mixture containing 40ng pB/KS/hG-CSF as DNA template, IX 
Pfu buffer (Strategene), 0.2mM dNTP, 0.5|LIM 5'GCSF-1 primer, O.SjiiM 3'GCSF primer 
(Figure 3-3) and 2.5imits Pfu DNA polymerase (Strategene, 2.5u/|al) was prepared and 
the PGR conditions were as follows: 94°C for 5 minutes, then 25 cycles of 94°C for 30 
seconds, 58°C for 30 seconds and 72®C for 30 seconds, followed by 1 cycle of 72°C for 
7 minutes. The PGR product was purified and then subjected to the reaction for 
A-tailing. A 10pi reaction mixture containing 300ng PGR product, IX Taq DNA 
polymerase reaction buffer (Promega), 2.5mM MgCl:，0.2mM dATP and 5 units Taq 
DNA polymerase (Promega, Su/^l) was incubated at 70°C for 2 hours. The A-tailed 
PGR product was first ligated to pGEM®-T vector. The target gene was then excised 
from the pGEM®-T/hG-CSF using Ncol and Not\, and cloned into pET/His/EK vector 
containing 6x consecutive histidine-tag and enterokinase (EK) site. The resulting 
plasmid was named pET/His/EK/hG-CSF. Then the whole gene cassette was excised 
using Accl and cloned into pTZ/Phas vector containing the phaseolin promoter and 
terminator, forming the plasmid pTZ/Phas/His/EK/hG-CSF (Figure 3-4). 
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Figure 3-4: Construction of chimeric gene pTZ/Phas/His/EK/hG-CSF 
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3.4.2 Cloning of pBK/Phas/SP/His/EK/hG-CSF 
The plasmid pGEM®-T/hG-CSF was constructed as described in section 3.4.1. 
Then the target gene was excised from the plasmid using Ncol and Notl, and cloned into 
pET/SP/His/EK vector containing partial phaseolin signal peptide sequence， 
histidine-tag and EK site, forming the plasmid pET/SP/His/EK/hG-CSF. The whole 
gene cassette was excised using Ndel and Accl, and cloned into pBK/Phas/SP vector 
containing the phaseolin promoter, the remaining part of phaseolin signal peptide 
sequence and terminator. The resulting plasmid was named 
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Hin&m Hindm 
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c “ 
pBK/Phas/SP/His/EK/hG-CSF 
Figure 3-5: Construction of chimeric gene pBK/Phas/SP/His/EK/hG-CSF 
46 
3.4.3 Cloning of pBK/Phas/SP/hG-CSF 
The nucleotide sequence (525bp) encoding for the hG-CSF mature peptide in 
pB/KS/hG-CSF was first amplified by PGR using two specific primers (Figure 3-3), 
which can introduce a 5' Nde\ site and a 3, AccI site to the target gene for sub-cloning. 
The PGR reaction mixture (except containing 5'GCSF-2 primer instead of 5'GCSF-l 
primer) and the PGR conditions were the same as section 3.4.1. The PGR product was 
purified and then subjected to the reaction of A-tailing as described in section 3.4.1. The 
A-tailed PGR product was ligated to the pGEM®-T vector. Then the target gene was 
excised from the pGEM®-T/hG-CSF-NoHis using Ndel and Acc\, and cloned into 
pBK/Phas/SP vector containing the phaseolin promoter, the phaseolin signal peptide 
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A-Ndel Accl-A 
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Figure 3-6: Construction of chimeric gene pBK/Phas/SP/hG-CSF 
49 
3.4.4 Confirmation of sequence fidelity of chimeric genes 
Before cloning the three chimeric genes into the Agrobacterium binary vector 
pBI121 to form the final constructs, cycle sequencing reaction was carried out by using 
the ABI Prism dRhodamine Terminator cycle sequencing to confirm the sequence 
fidelity of the three chimeric genes. Two specific primers (Figure 3-7) containing part of 
the phaseolin promoter and terminator sequence, were used in DNA sequencing to 
confirm that there were no frame shifts in between the junctions of the chimeric genes 
and no errors occurred in the PGR product of hG-CSF mature peptide sequence. 
SThaSpro 1 5'- CCATCCATCCAGAGTACTACT -3， 
3Thaster 1 5'- ATTATACTGTTACATGGTCGG -3, 
Figure 3-7: Primers for confirmation of sequence fidelity of the chimeric genes 
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3.4.5 Cloning of chimeric genes into Agrobacterium binary vector 
The Agrobacterium binary vector pBI121 consists of the right border (RB) 
and left border (LB) of T-DNA, neomycin phosphotransferase II (NPT II) selectable 
marker and a-glucurondiase (GUS) screenable marker genes. RB and LB were used to 
transfer the DNA region in between them to the plant genome. NPT II gene was used to 
screen the plant transformants in culture medium containing kanamycin while GUS 
gene was used to confirm the transformants by enzyme assay. The three chimeric genes 
in plasmids pTZ/Phas/His/EK/hG-CSF, pBK/Phas/SP/His/EK/hG-CSF and 
pBK/Phas/SP/hG-CSF were excised using Hindlll, and cloned into the Agrobacterium 
binary vector pBI121 to form the final constructs. They were named 
pBI/Phas/His/EK/hG-CSF (H), pBI/Phas/SP/His/EK/hG-CSF (SH) and 
pBI/Phas/SP/hG-CSF (S), respectively, and were ready for Agrobacterium and plant 





RB NoSpro NPT II Noster "1 35Spro GUS Noster LB 
^ ^ ^ ^ ^ ^ pBI121 
Figure 3-8: Cloning of chimeric genes into Agrobacterium binary vector pBI121 
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3.5 Expression in Arabidopsis 
Firstly, the three chimeric genes constructed in section 3.4.5 were used to 
transform Agrobacterium GV3101/pMP90 (Koncz and Schell, 1986). Then the model 
plants Arabidopsis were transformed by Agrobacterium-mQdidiiQd method through 
vacuum infiltration. Transgenic plants were identified and the expression of the 
chimeric gene was analyzed by molecular and biochemical assays. Finally, functional 
assay was performed to analyze the biological activity of the recombinant hG-CSF 
produced in the seeds of transgenic Arabidopsis. 
3.5.1 Agrobacterium GV3101/pMP90 transformation 
By electroporation, Agrobacterium tumefaciens GV3101/pMP90 (Koncz and 
Schell, 1986) was transformed with the three chimeric gene constructs (section 3.4.5), 
namely, pBI/Phas/His/EK/hG-CSF (H), pBI/Phas/SP/His/EK/hG-CSF (SH) and 
pBI/Phas/SP/hG-CSF (S). 
An aliquot (40|il) of Agrobacterium GV3101/pMP90 competent cells was thawed 
on ice. Then the competent cells were gently mixed with 1|LI1 of plasmid DNA (�500ng) 
and put on ice for 1 minute. The Gene Pulser apparatus (BioRad) was set as 25|j,F, 
2.5kV and 600ohms, and the cell-DNA mixture was transferred to a pre-chilled 
electroporation cuvette (Bio-Rad) and shaked to the bottom of the cuvette without any 
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bubbles. Then an electric pulse was applied to the cuvette. After pulsing, 1 ml of SOC 
medium (2% Bacto tryptone，0.5%Bacto yeast extract, lOmM NaCl, 2.5mM KCl, 
lOmM MgCh, lOmM MgSCU and 20mM glucose) was added to the cuvette. The cells 
were quickly resuspended and transferred to a 5ml polypropylene round-bottom tube 
(Falcon) with shaking at 28�C for 2 hours. Then 5|LI1, 50|LI1 and the remaining cells were 
spread on LB plates supplemented with 50mg/L rifampicin, 25mg/L gentamycin and 
50mg/L kanamycin. The plates were incubated at 28�C for 2 days to select the 
transformed Agrobacterium colonies. 
3.5.2 Arabidopsis transformation 
3.5.2.1 Plant materials 
Seeds of Arabidopsis thaliana ecotype Columbia-0 (Col-0) were sowed onto soil 
(Metro-Mix®200 Growing medium, Scotts®) and kept at 4 � C for 2 days as an imbibition 
period to optimize and synchronize the germination. The seeds were then allowed to 
germinate and grow in growth chamber under conditions of 16 hours light (about 
100|aEW/s; with 2000 lux cool fluorescent lightings) / 8 hours dark cycles at 22�C, in 
70% humidity for four to six weeks. Plants were irrigated weekly with Arabidopsis 
fertilizer [5mM KNO3, 2.5mM KPO4 (pH 5.5), 2mM MgSCU，2mM Ca(N03)2，0.5mM 
FeEDTA，70|IM boric acid, 14|liM MNCH, 5 | I M CUSO4，L|AM ZNS04, 0 .2) IM NAMO04, 
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10|iM NaCl and 0.01|iM CuCy. The plants, regarded as Ro, were ready for vacuum 
infiltration when the primary inflorescence was 10 - 15 cm tall and the secondary 
inflorescences were appearing at the rosette. 
3.5.2.2 Vacuum infiltration 
The method was originally developed by Bechtold et al. (1993) and modified by 
Lam (CUHK). When Ro plants were ready for transformation, 1ml overnight starter 
culture of transformed Agrobacterium containing the chimeric gene construct was added 
to a 500ml YEP medium (lOg/L Bacto peptone, lOg/L yeast extract and 5g/L NaCl) 
with 50mg/L rifampicin, 25mg/L gentamycin and 50mg/L kanamycin. The culture was 
incubated overnight at 28®C with shaking (300 - 350 rpm), until culture OD500 was 
greater than 2.0. Then the culture was spun down and resuspended in 1 liter of 
infiltration medium [2.2g/L MS salts (Gibco), IX B5 vitamins (0.1 g/L myoinositol, 
O.Olg/L thiamine-HCl, Img/L nicotine acid and Img/L pyridoxine-HCl), 50g/L sucrose, 
0.5g/L MES, 0.044|aM benzylaminopurine and 0.02% SilwetiM L-77, pH 5.7]. The 
resuspended culture was poured into an IL beaker inside a vacuum desiccator and was 
ready for plant transformation. 
Right before infiltration, all siliques were removed from the Ro plants while the 
flower clusters were left intact. Then the plants were inverted and immersed in the 
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resuspended culture so that the whole plants, especially the flower clusters, were 
submerged. A vacuum was applied until bubbles were formed in the bacterial culture 
and held for 10 minutes. Then the vacuum was quickly released. The Ro plants were 
briefly drained and allowed to grow until completion of flowering. Ri seeds were then 
collected from individual infiltrated plants after they dried out and used in the screening 
of transgenic Ri Arabidopsis. 
3.5.3 Screening of successful Ri transformants 
For each Ro plant, 100|LI1 of Ri seeds ( �2 5 0 0 seeds) were surface-sterilized in 
Clorox solution (Sodium hyprochlorite, 5.25%) for 3 minutes by vortexing and shaking, 
followed by 1 minute washing in 1ml sterile distilled water for 3 times. Then the sterile 
seeds were evenly distributed on circular plate containing MS medium (4.3g/L MS salts 
(Gibco), 1% sucrose, 0.5g/L MES and 0.8% bacto-agar, pH 5.7) with 50mg/L 
kanamycin. The plates were sealed with parafilm and placed in 4°C refrigerator for 2 
days to imbibe. Then the seeds were allowed to grow in the growth chamber with the 
growing conditions as described in section 3.5.2.1. After 5 to 7 days, transgenic Ri 
Arabidopsis were selected out as green plants and transferred to MS square plate 
containing 50mg/L kanamycin for further growth. After one to two weeks, the Ri 
transformants were transferred to soil. Each transformant was enclosed with a hollow 
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plastic cylinder to ensure self-fertilization and allowed to grow until they flowering. R2 
seeds from each Ri plant were then collected after the plants dried out. 
3.5.4 Screening of hemizygous and homozygous transgenic Arabidopsis 
For screening of hemizygous transgenic Ri Arabidopsis, about 50 - 100 R2 seeds 
were surface-sterilized and plated on MS medium containing 50mg/L kanamycin for 
selection and growth as described in section 3.5.3. After one to two weeks, the number 
of green transformants and yellow non-transformants from each plate were counted. 
According to Mendelian law, those R2 plants in each MS plate, giving 3 survival to 1 
death ratio with acceptable Chi-square value, were the offsprings of a hemizygous 
transgenic Ri Arabidopsis, Therefore, about eight to ten R2 plants in each selected plate 
were allowed to grow for screening of homozygous transgenic R2 plants. Two-third of 
the transgenic R2 plants in each selected plate would be hemizygous while one-third was 
homozygous. 
For screening of homozygous transgenic K2 Arabidopsis, about 50 - 100 R3 seeds 
from each R2 plants were surface-sterilized and plated on MS medium containing 
50mg/L kanamycin for selection and growth as described in section 3.5.3. Finally, 
homozygous transgenic R2 Arabidopsis were selected out from plates with all the (R3) 
plants survived in the selection medium. 
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3.5.5 GUS assay 
GUS assay was performed by using the following standard protocol of Jefferson et 
al. (1987). Young plantlet was placed into an eppendorf tube containing the GUS 
staining solution [lOOmM Na-phosphate buffer (pH 7.0)，0.1% Triton X-100, ImM 
EDTA, 0.5mM K3Fe(CN)6，0.05mM K4Fe(CN)6 and 0.5mg/ml X-glucuronide (X-gluc, 
dissolved in DMF)] and incubated at 37°C for 1 - 3 days. Then the green chlorophyll 
background of the plantlet was removed by replacing the staining solution with 70% 
ethanol and continuing the incubation until the background was clear. 
3.5.6 Genomic DNA extraction 
Genomic DNA was extracted from Arabidopsis leaves by using the CTAB protocol 
of Doyle et al. (1990). Fresh leaves ( �5 0 m g ) were placed in an eppendorf tube and 
treated with liquid nitrogen. Five drops of CTAB extraction buffer [2% CTAB, lOOmM 
Tris-HCl (pH 8.0), 1.4M NaCl, 20mM EDTA and 0.2% a-mercaptoethanol] and a pinch 
of sterile sand were added into the eppendorf. The leaves were then ground into 
homogenate with glass rod. Five hundred )il CTAB extraction buffer was added to the 
homogenate, followed by 60°C incubation for 30 minutes with periodic mixing. The 
plant lysate was then mixed gently with 500|il chloroform : isoamyl alcohol (24:1，v/v) 
and centrifuged at 13,000 rpm at 4°C for 5 minutes. The upper aqueous layer was 
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transferred to a new eppendorf tube and mixed with 330^1 cold isopropanol. The 
mixture was then incubated at 一 2 0 � C for 1 hour and centrifuged at 13,000 rpm at 4®C 
for 15 minutes. The supernatant was discarded and the pellet was washed with 70% 
ethanol. After centrifugation and removing the ethanol, the pellet was dried under 
vacuum for 10 minutes at room temperature. The dried DNA pellet was resuspended in 
SO i^l TE buffer [lOmM Tris-HCl (pH 8.0) and ImM EDTA]. The DNA concentration 
was determined by OD260 measurement using a spectrophotometer and the quality of 
DNA was checked by gel electrophoresis in a 1% agarose/TAE (0.04M Tris-acetate and 
ImM EDTA) gel. 
3.5.7 Southern blot analysis 
Genomic DNA (10|Lig) was digested overnight with HindlW at 3TC. Then the 
digested DNA was separated by gel electrophoresis in a 0.8% agarose/TAE gel and 
transferred to a positively charged nylon membrane (Boehringer Mannheim) using 
VacuGeneXL Vacuum Blotting System (Pharmacia Biotech). 
A sense DIG-labeled DNA probe for the hG-CSF mature peptide sequence (525bp) 
was prepared by using the DIG DNA Labeling Kit (Boehringer Mannheim) via PGR 
amplification. A lOOjil PGR reaction mixture containing 50ng PGR product of hG-CSF 
coding sequence (obtained in section 3.4.1) as DNA template, IX PGR buffer 
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(Promega), 0.5mM MgCb，0.02mM DIG dNTPs, O.ljaM 5'GCSF-l primer (Figure 3-3) 
and Sunits Taq DNA polymerase (Promega, 5u/|il) was prepared and the PCR 
conditions were as follows: 94°C for 2 minutes, then 55 cycles of 94°C for 20 seconds, 
53°C for 30 seconds and 72�C for 2 minutes, followed by 1 cycle of 72�C for 10 
minutes. The yield of the DNA probe was determined by a spot test with a DIG-labeled 
control. 
Hybridization with the sense DIG-labeled DNA probe and detection using the 
Anti-Digoxigenin-AP (alkaline phosphatase) were preformed according to the method 
described in the DIG Nucleic Acid Detection Kit (Boehringer Mannheim). 
3.5.8 Total RNA extraction from developing siliques 
Total RNA was extracted from Arabidopsis developing siliques by using the 
method of Altenbach et al. (1989). Fresh developing siliques (�lOOmg) were placed in 
a mortar and ground into fine powder with a pestle by adding liquid nitrogen. Then the 
powder was transferred to an eppendorf tube and mixed with 0.5ml extraction buffer 
[O.IM LiCl, O.IM Tris-HCl (pH 8.0), O.IM EDTA, 1% SDS and 1:1 (v/v) phenol]. The 
mixture was incubated at 55®C for 15 minutes with periodic mixing and then mixed 
with 0.25ml chloroform : isoamyl alcohol (24:1, v/v) by vortexing. The mixture was 
centrifuged at 14,000 rpm for 5 minutes at room temperature. The upper aqueous layer 
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was transferred to a new eppendorf tube and mixed with equal volume of 4M LiCl. The 
mixture was stored at 4°C overnight and then centrifuged at 14,000 rpm at 4°C for 10 
minutes. The supernatant was discarded and the pellet was washed with 2M LiCl. After 
centrifugation and removing the supernatant, the pellet was resuspended in 0.25ml 
DEPC-treated water and then mixed with 25|al 3M sodium acetate (pH 5.0) and two 
volumes of 100% ethanol. The mixture was kept at - 2 0 � C for 1 hour and then 
centrifuged at 14,000 rpm at 4°C for 30 minutes to obtain the pellet. The pellet was 
washed with 70% ethanol twice and dried under vacuum for 10 minutes. The dried 
RNA pellet was resuspended in 30fal DEPC H2O. The RNA concentration was 
determined by OD260 measurement using a spectrophotometer and the quality of RNA 
was checked by gel electrophoresis in a 1% agarose/formaldehyde gel. 
3.5.9 Northern blot analysis 
Total silique RNA (lOjig) was separated by gel electrophoresis in a 1% 
agarose/formaldehyde gel and transferred to a positively charged nylon membrane 
(Boehringer Mannheim) using capillary transfer method for overnight. 
An anti-sense DIG-labeled DNA probe for the hG-CSF mature peptide sequence 
(525 bp) was prepared as described in section 3.5.7 except 3'GCSF primer was used in 
the PCR reaction mixture instead of 5'GCSF-l primer (Figure 3-3). The yield of the 
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DNA probe was determined by a spot test with a DIG-labeled control. 
Hybridization with the anti-sense DIG-labeled DNA probe and detection using the 
Anti-Digoxigenin-AP (alkaline phosphatase) were preformed according to the method 
described in the DIG Nucleic Acid Detection Kit (Boehringer Mannheim). 
3.5.10 Protein extraction and Tricine SDS-PAGE 
Total seed protein was extracted from 0.05g mature Arabidopsis seeds by grinding 
the seeds into powder and mixing with 1ml protein extraction buffer [0.25M NaCl and 
0.05M NaP04 (pH 7.0)]. The homogenate was then centrifuged at 14,000 rpm for 15 
minutes. The clear supernatant was transferred to a new eppendorf tube and saved as 
seed total protein extract (STPE). The protein concentration was determined by the 
method of Bicinochoninic Acid (BCA) using bovine serum albumin (BSA) as a 
standard. 
The quality of protein was checked by tricine-SDS-PAGE (Schagger et al.，1987). 
STPE (lOOfig) was mixed with equal volume of 2X sample loading buffer (8% SDS, 
24% glycerol, lOOmM Tris-base, 4% a-mercaptoethanol and trace amount of 
bromophenol blue) and incubated at 40°C for 30 minutes. Then the samples were loaded 
into the wells and separated by 16.5% tricine-SDS-PAGE. Anode buffer (0.2M 
Tris-base, pH 8.9) and cathode buffer (O.IM Tris-base, O.IM Tricine and 0.1% SDS, pH 
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8.25) were used in the gel electrophoresis. After electrophoresis, the tricine-gel was 
stained in Coomassie Brilliant Blue solution (Ig/L Coomassie brilliant blue G-250 and 
1% methanol) and destained in destaining solution (methanol: 100% glacial acetic acid : 
water, 20 : 6 : 55). 
3.5.11 Western blot analysis 
Before blotting, total seed protein (100|ig) extracted from mature Arabidopsis 
seeds, was separated by 16.5% tricine-SDS-PAGE. Then the tricine-gel, without 
staining, was equilibrated in Dunn transfer buffer (lOmM NaHCOa, 3mM NasCOs and 
0.02% SDS) for 20 minutes. At the same time, a piece of polyvinylidene difluoride 
(PVDF) membrane was first treated with 100% methanol for 1 minute and then 
equilibrated in Dunn transfer buffer for 20 minutes. The protein in the tricine-gel was 
blotted onto PVDF membrane by using Trans-blot electrophoretic transfer cell 
(Bio-Rad). The transfer cell was filled with Dunn transfer buffer and placed in an 
ice-bath. Electro-transfer was performed at 44V for 1 hour. 
After electroblotting, the membrane was subjected to immunodetection using 
AURORA Western Blot Chemiluminescent Detection System (ICN). The membrane 
was first placed in Dunn transfer buffer for 15 minutes and then rinsed twice with IX 
phosphate buffered saline (PBS) (58mM Na2HP04, 17mM NaHzPOjSHzO and 68mM 
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NaCl) for 5 minutes. The membrane was incubated in blocking buffer (IX PBS, 0.2% 
r p » M 
Aurora blocking reagent and 0.1% Tween-20) for 1 hour and then for another hour in 
blocking buffer containing 0.2|Lig/ml anti-hG-CSF polyclonal antibody (R&D Systems 
Inc.) Unbound primary antibody was removed by washing the membrane in blocking 
buffer for 5 minutes (2 times). Then the membrane was incubated in blocking buffer 
with 1 : 5000 anti-goat IgG secondary antibody-alkaline phosphatase conjugate for 1 
hour. Again the unbound secondary antibody was removed by washing the membrane in 
blocking buffer for 5 minutes (3 times). Then the membrane was washed in assay buffer 
[20mM Tris-HCl (pH 9.8), ImM MgCh] for 2 minutes (2 times). After adding 1ml 
chemiluminescent substrate solution, the membrane was ready for film exposure and 
development. 
3.5.12 Functional analysis 
The in vitro biological activity of hG-CSF produced in seeds of transgenic 
Arabidopsis was determined in a cell proliferation assay using a factor-dependent 
murine myeloblastic cell line NFS-60. NFS-60 cells are totally dependent on 
interleukin-3 (IL-3) or macrophage colony-stimulating factor (M-CSF) for growth and 
maintenance of their viability in vitro. These cells also proliferate in response to 
hG-CSF. Therefore, NFS-60 cells were used in this functional analysis. A rapid 
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colorimetric assay (MTT assay) (Mosmann, 1983) was performed to determine the 
proliferation ofNFS-60 cells which was induced by the hG-CSF produced in transgenic 
Arabidopsis seeds. 
3.5.12.1 Culture ofNFS-60 cells 
The cryovial containing about 1 ml NFS-60 cells (ATCC®) was quickly retrieved 
from the liquid nitrogen storage tank and incubated in a 3TC water bath with regular 
agitation to thaw the cells. Then all cells from the cryovial were transferred into a 15ml 
centrifuge tube. About 15 ml complete RPMI 1640 medium [16.2g/L RPMI 1640 
powder (Gibco), lOmM HEPES, ImM sodium pyruvate, 1.5g/L sodium bicarbonate, 
O.OSmM a-mercaptoethanol, 5ng/ml human recombinant macrophage colony 
stimulating factor (M-CSF) (PeproTech, USA), 10% fetal bovine serum (FBS) and 1% 
PSN (50|ig/ml penicillin G sodium salt, SO^g/ml streptomycin sulfate and 100|ag/ml 
neomycin sulfate)] was added to the cells drop wise with regular agitation to dilute the 
cryopreservative (DMSO) and prevent from the sudden change of osmolality in cells. 
Then the cell mixture was centrifuged at 1000 rpm for 10 minutes at 20°C. The cell 
pellet was resuspended in 5ml pre-warmed complete RPMI 1640 medium. Ten |LI1 cells 
mixed with lO i^l trypan blue, which only stained non-viable cells in blue color, were 
then transferred onto a haemocytometer. The concentration and viability of the cells 
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were determined by counting and observing the cells under microscope. Suitable 
amount of cells were seeded to the fresh complete RPMI 1640 medium in culture flask 
so that the initial cell density was 2.5 x cells/ml. The cells were then allowed to 
grow at 3TC in 5% CO2 incubator followed by every 2 - 3 day passage as the 
maximum cell density should not exceed 5 x 10^  cells/ml. 
3.5.12.2 MTT assay 
Tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide) is a yellow substrate. The dehydrogenase enzymes in active mitochondria of 
living cells can cleave the tetrazolium ring of MTT and convert it to purple insoluble 
crystals inside the cells. DMSO can break down the cells and then dissolve the purple 
crystals. The number of viable cells is proportional to the intensity of purple color 
measured by Microplate Spectrophometer at OD570. Therefore, MTT assay is a good 
assay for determination of NFS-60 cell proliferation induced by hG-CSF expressed in 
transgenic seeds. 
In this study, NFS-60 cells were first incubated in culture flask until the cell 
density was about 3 x 10^  cells/ml. Then the cells were transferred to a 50ml tube and 
centrifuged at 1500 rpm for 5 minutes. The supernatant was discarded and the cell pellet 
was resuspended in a suitable volume of RPMI 1640 medium [complete RPMI 1640 
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medium, without 10% FBS and 5ng/ml human M-CSF (PeproTech, USA)] so that the 
cell density was 1 x 10^  cells/ml. One-hundred \x\ cell culture ( � 1 0 0 0 0 cells) was added 
to each well of 96-well microplate and starved for 4 - 6 hours at 37®C in 5% CO2 
incubator. Then lOOpl of serially dilution of total seed protein extract (from transgenic 
seeds) in RPMI 1640 medium (complete RPMI 1640 medium, without 10% FBS and 
5ng/ml human M-CSF, but with 20% heat inactivated FBS) was added to each well 
triplicate. At the same time, lOOjil of serially dilution of purified rhG-CSF produced 
from E. coli (PeproTech, USA) was added to each well triplicate as a standard curve. 
The cells were then incubated at 37®C for 48 hours. Twenty i^l MTT solution (5mg/ml 
MTT in HPBS, pH 7.4) was added to each well and then incubated for 2 hours at 7>TC. 
The plate was centrifuged at 2000 rpm for 10 minutes. All supernatant was removed and 
100|il DMSO was added to each well to break down the cells and dissolve the purple 
crystals. The intensity of purple color in each well was measured by using a Microplate 
Spectrophometer at OD570. 
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3.6 Expression in tobacco 
Similar to section 3.5 of expression in Arabidopsis system, the three chimeric 
genes constructed in section 3.4.5 were first used to transform Agrobacterium 
LBA4404/pAL4404 (Hoekema et al., 1983). Then the model tobacco plants were 
transformed by Agrobacterium-mQdidiiQd method through leaf-disc technique. 
Transgenic plants were selected and the expression of the chimeric gene was analyzed 
by molecular and biochemical assays. Finally, functional assay was performed to 
analyze the biological activity of the recombinant hG-CSF produced in the seeds of 
transgenic tobacco. 
3.6.1 Agrobacterium LBA4404/pAL4404 transformation 
By electroporation, Agrobacterium tumefaciens LBA4404/pAL4404 (Hoekema et 
al., 1983) was transformed with the three chimeric gene constructs made in section 3.4.5， 
namely pBI/Phas/His/EK/hG-CSF (H)，pBI/Phas/SP/His/EK/hG-CSF (SH) and 
pBI/Phas/SP/hG-CSF (S). The method used was the same as described in section 3.5.1. 
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3.6.2 Tobacco transformation 
3.6.2.1 Plant materials 
Seeds of wild type tobacco {Nicotiana tabacum L. cv Xanthin. nc) were 
surface-sterilized in Clorox solution (Sodium hyprochlorite, 5.25%) for 3 minutes by 
vortexing and shaking, followed by 1 minute washing in 1ml sterile distilled water for 3 
times. Then the sterile seeds were plated on MS medium (4.3g/L MS salts (Gibco), 1% 
sucrose, 0.5g/L MES and 0.8% bacto-agar, pH 5.7) in magenta box and allowed to 
germinate in growth chamber under conditions of 16 hours light / 8 hours dark cycles at 
25°C. After one month, sterile tobacco leaves were cut from the plant and used for 
tobacco transformation. 
3.6.2.2 Tobacco transformation using leaf-disc technique 
Tobacco transformation was performed using the method of Fisher et al. (1995). A 
single colony of Agrobacterium harboring the chimeric gene construct was inoculated in 
3ml LB medium (lOg/L Bacto peptone, lOg/L yeast extract and 5g/L NaCl) containing 
25mg/L streptomycin and 50mg/L kanamycin. The culture was incubated overnight at 
28°C with shaking (300 - 350 rpm), until the culture reaching an OD620 > 1.0. Then the 
culture was spun down and washed with inoculation medium [4.3g/L MS salts (Gibco), 
3% sucrose，Img/L BA, 0.2mg/L IBA and 100|aM As, pH 5.7] for 3 times. The cell 
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pellet was resuspended in 3 ml inoculation medium and was ready for tobacco 
transformation. 
Young leaves from one-month-old tobacco were cut into small square discs (0.5 x 
0.5 cm ). Then the leaf discs were immersed in lOX diluted Agrobacterial culture for 10 
minutes. The leaf discs were first transferred to sterile filter paper for excess 
Agrobacterium removal and then transferred onto solidified co-cultivation medium 
[4.3g/L MS salts (Gibco)，3% sucrose, 0.8% agar, Img/L BA, 0.2mg/L IBA and lOO i^M 
As, pH 5.7] for 2 days at 25�C. 
3.6.3 Regeneration of transgenic tobacco 
After co-cultivation, the leaf discs were transferred onto selection shooting 
medium [4.3g/L MS salts (Gibco), 3% sucrose, 0.8% agar, Img/L BA, 0.2mg/L IBA, 
500mg/L carbenicilin and lOOmg/L kanamycin pH 5.7] and incubated in growth 
chamber under the conditions of 16 hours light / 8 hours dark cycles at 25®C for callus 
and shoot formation. After 2 - 3 weeks, calli were formed on the leaf discs and 
regenerated shoots were grown out after 2 more weeks. Then the regenerated shoots 
were cut off and transferred to selection rooting medium [4.3g/L MS salts (Gibco), 3% 
sucrose, 0.8% agar, O.lmg/L IBA, 500mg/L carbenicilin and lOOmg/L kanamycin, 
pH 5.7] for rooting. After 3 - 4 weeks, the regenerated transgenic tobacco were 
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transferred to soil and grown in greenhouse for further expression analysis. 
3.6.4 GUS assay 
Young tobacco leaves were used for GUS assay as described in section 3.5.5. 
3.6.5 Genomic DNA extraction 
Genomic DNA was extracted from tobacco leaves by using the CTAB protocol of 
Doyle et al (1990). 
3.6.6 Southern blot analysis 
Genomic DNA (20|^g) was digested overnight with HindWl at 37�C. Then the 
digested DNA was separated by gel electrophoresis in a 0.8% agarose/TAE gel and 
transferred to a positively charged nylon membrane for Southern blot hybridization and 
detection as described in section 3.5.7. 
3.6.7 Total RNA extraction from immature seeds 
Total RNA was extracted from tobacco immature seeds (18 一 20 days after 
flowering, DAF) by using the method of Altenbach et al. (1989) as described in section 
3.5.8. 
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3.6.8 Northern blot analysis 
Total seed RNA (lOjiig) was separated by gel electrophoresis in a 1% 
agarose/formaldehyde gel and then transferred to a positively charged nylon membrane 
for hybridization and detection as described in section 3.5.9. 
3.6.9 Protein extraction and Tricine SDS-PAGE 
Total seed protein was extracted from O.lg mature tobacco seeds with 1ml protein 
extraction buffer and 100|ig protein extract was separated by 16.5% tricine-SDS-PAGE 
as described in section 3.5.10. 
3.6.10 Western blot analysis 
Seed total protein extract (100|ag) was separated in the tricine-gel and blotted onto 
the PVDF membrane for western blot analysis as described in section 3.5.11, 
3.6.11 Functional analysis 
Similar to section 3.5.12, the in vitro biological activity of hG-CSF produced in 
seeds of transgenic tobacco was determined in a cell proliferation assay using a 
factor-dependent murine myeloblastic cell line NFS-60. 
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3.6.11.1 Culture of NFS-60 cells 
The NFS-60 cells were thawed and cultured by 2 - 3 day passage as described in 
section 3.5.12.1. 
3.6.11.2 MTT assay 
MTT assay was carried out as described in section 3.5.12.2 except 100|LI1 of serially 
dilution of total seed protein extract (from transgenic tobacco seeds) in RPMI 1640 
medium was added to each well of 96-well microplate. 
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Chapter 4: Results 
4.1 Chimeric gene construction 
4.1.1 Cloning of pTZ/Phas/His/EK/hG-CSF 
The chimeric gene construct pTZ/Phas/His/EK/hG-CSF under the control of the 
seed-specific phaseolin promoter and terminator was made. Without the phaseolin 
signal peptide, transgenic plants are expected to have their hG-CSF protein present in 
the seed cytosol. The 5' cleavable histidine-tag in front of the target gene will facilitate 
the purification of the expressed proteins from the seed total protein extract by forming 
a stable complex with Nickel in the purification column at a desired range of pH. 
The construct was checked by Hindlll and Xmnl double restriction enzymes 
digestion (Figure 4-1 and 4-2). In addition, DNA sequencing, using two specific primers 
(Figure 3-7), was carried out to confirm the in frame insertion of the chimeric gene. 
After confirmation, the fragment of the whole gene cassette (�3.03kb)，flanked by 
Hindlll, was cut and eluted from the gel (Figure 4-2). Then the purified chimeric gene 
fragment was cloned into the Agrobacterium binary vector pBI121 to form the final 
construct pBI/Phas/His/EK/hG-CSF (H) for Agrobacterium and plant transformation. 
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�3 . 0 3 k b — 
Hindlll ~ Hindlll 
\ Phaspro His EK hG-CSF Phaser / 
N. pTZ/Phas/His/EK/hG-CSF (�5.85kb) ^ 
�0 . 9 5 k b �1 . 8 7 k b 
Xmnl 
Figure 4-1: Restriction enzymes map of pTZ/Phas/His/EK/hG-CSF 
The chimeric gene construct was digested by Hindlll and Xmnl. Three 
fragments, 0.95kb, 1.87kb and 3.03kb, were formed. 
1 2 
3.0kb ^ , Cut and eluted 
2.0kb from the gel for 




Figure 4-2: Gel electrophoresis of pTZ/Phas/His/EK/hG-CSF after digestion 
Three desired bands (0.95kb, 1.87kb and 3.03kb) were seen in the gel 
after Hindlll and Xmnl digestion of the chimeric gene construct. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: pTZ/Phas/His/EK/hG-CSF (Hindlll and Xmnl digested) 
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4.1.2 Cloning of pBK/Phas/SP/His/EK/hG-CSF 
The chimeric gene construct, pBK/Phas/SP/His/EK/hG-CSF, containing the 
phaseolin promoter, phaseolin signal peptide and 5' cleavable histidine-tag, was made. 
With the phaseolin signal peptide, transgenic plants are expected to have their hG-CSF 
protein deposited in protein bodies of transgenic seeds while the histidine-tag will be 
used in protein purification as described in section 4.1.1. 
As before, the construct was checked by HindlW and Xmn\ double restriction 
enzymes digestion (Figure 4-3 and 4-4) and DNA sequencing. After confirmation, the 
fragment of the whole gene cassette (�3.07kb)，flanked by HindlW, was cut and eluted 
from the gel (Figure 4-4). The purified chimeric gene fragment was cloned into the 
Agrohacterium binary vector pBI121 to form the final construct 
pBI/Phas/SP/His/EK/hG-CSF (SH) for Agrobacterium and plant transformation. 
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�3 . 0 7 k b  
Hindlll Hinmi 
\ Phaspro SP His EK hG-CSF Phaster / 
v . pBK/Phas/SP/His/EK/hG-CSF ( �6 k b ) � 
�0 . 9 7 k b �1 . 9 6 k b 
Xmnl 
Figure 4-3: Restriction enzymes map of pBK/Phas/SP/His/EK/hG-CSF 
The chimeric gene construct was digested by Hindlll and Xmnl. Three 
fragments, 0.97kb, 1.96kb and 3.07kb, were formed. 
1 2 
• n 
3 Okb ^ Cut and eluted 
^wmmmmmm^ from the gel for 
~ c l o n i n g to pBI121 
1.6kb  
l.Okb —— 
Figure 4-4: Gel electrophoresis of pBK/Phas/SP/His/EK/hG-CSF after digestion 
Three desired bands (0.97kb, 1.96kb and 3.07kb) were seen in the gel 
after Hindlll and Xmnl digestion of the chimeric gene construct. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: pBK/Phas/SP/His/EK/hG-CSF (Hindlll and Xmnl digested) 
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4.1.3 Cloning of pBK/Phas/SP/hG-CSF 
The chimeric gene construct pBK/Phas/SP/hG-CSF was made with the phaseolin 
promoter and phaseolin signal peptide. As described in section 4.1.2，transgenic plants 
are expected to have their hG-CSF protein deposited in protein bodies of transgenic 
seeds. However, no 5' cleavable histidine-tag was fused with the target gene in order to 
check whether the histidine-tag would affect the expression of hG-CSF in plants. 
As before, the construct was checked by Hin&Wl and Xmnl double restriction 
enzymes digestion (Figure 4-5 and 4-6) and DNA sequencing. After confirmation, the 
fragment of the whole gene cassette ( �3 k b ) , was cut and eluted from the gel (Figure 
4-6), and cloned into the Agrobacterium binary vector pBI121 to form the final 
construct pBI/Phas/SP/hG-CSF (S) for Agrobacterium and plant transformation. 
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�3 k b  
Hindlll Hinmi 
\ Phaspro SP hG-CSF Phaster � 
N. pBK/Phas/SP/hG-CSF (�5.93kb) J 
�0 . 9 7 k b �1 . 9 6 k b 
Xmnl 
Figure 4-5: Restriction enzymes map of pBK/Phas/SP/hG-CSF 
The chimeric gene construct was digested by Hindlll and Xmnl. Three 
fragments, 0.97kb, 1.96kb and 3kb, were formed. 
1 2 
3.0kb — — — C u t and eluted 
2.0kb i m P ^ from the gel for 
IhiMiii^^wi^ cloning to pBI 121 
1.6kb ~ ~ 
l.Okb _ 
Figure 4-6: Gel electrophoresis of pBK/Phas/SP/hG-CSF after digestion 
Three desired bands (0.97kb, 1.96kb and 3kb) were seen in the gel after 
Hindlll and Xmnl digestion of the chimeric gene construct. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: pBK/Phas/SP/hG-CSF (Hindlll and Xmnl digested) 
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4.1.4 Cloning of chimeric genes into Agrobacterium binary vector 
After confirmation of sequence fidelity by DNA sequencing, the three chimeric 
genes in plasmids pTZ/Phas/His/EK/hG-CSF, pBK/Phas/SP/His/EK/hG-CSF and 
pBK/Phas/SP/hG-CSF were excised using HindlW, and cloned into the Agrobacterium 
binary vector pBI121 to form the final constructs. They were named as 
pBI/Phas/His/EK/hG-CSF (H)， pBI/Phas/SP/His/EK/hG-CSF (SH) and 
pBI/Phas/SP/hG-CSF (S), respectively. Upon completion, all three constructs were 
checked by Hindlll single restriction enzyme digestion and gel electrophoresis (Figure 
4-7 and 4-8). The results showed that all the constructs were made correctly and ready 
for Agrobacterium and plant transformation. 
�3 k b  
Hinmi Hindlll 
RB NPT II gene Chimeric gene GUS gene LB ^ ^ ^ 
Construct H or SH or S ( �1 8 k b ) 夕 
pBI121 - 15kb ‘ " " " " 
Figure 4-7: Restriction enzyme map of construct H, SH and S 
The chimeric gene constructs were digested by HindWl. Two fragments, 
15kb and 3kb，were formed. 
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H SH S 
1 2 3 4 
H 
3.0kb 一 �3 . � k b 
Figure 4-8: Gel electrophoresis of construct H，SH and S after digestion 
Two desired bands (15kb and 3kb) were seen in the gel after Hindlll 
digestion of the chimeric gene constructs. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: pBI/Phas/His/EK/hG-CSF (H) 
Lane 3: pBI/Phas/SP/His/EK/hG-CSF (SH) 
Lane 4: pBI/Phas/SP/hG-CSF (S) 
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4.2 Expression in Arabidopsis 
4.2.1 Agrobacterium GV3101/pMP90 transformation 
By electroporation, Agrobacterium GV3101/pMP90 (Koncz and Schell, 1986) was 
transformed with either one of the three chimeric gene constructs (H, SH and S) made 
in section 4.1.4. The plasmid DNAs were isolated from the transformed Agrobacterium 
using Wizard Minipreps Kit (Promega) and digested with HindWl to confirm the 
successful transformation of Agrobacterium by electroporation. As described in section 
4.1.4，two fragments (15kb and 3kb) were formed after HindlW digestion of the plasmid 
DNAs. The results showed that the transformation was successful (Figure 4-9) and the 
transformed Agrobacterium was ready for Arabidopsis transformation. 
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1 2 3 4 
15kb 
^ ~ • �3 k b 
Figure 4-9: Gel electrophoresis of plasmid DNAs from transformed 
Agrobacterium GV3101/pMP90 after digestion with Hindlll 
Two desired bands (15kb and 3kb) were seen in the gel. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: pBI/Phas/His/EK/hG-CSF (H) 
Lane 3: pBI/Phas/SP/His/EK/hG-CSF (SH) 
Lane 4: pBI/Phas/SP/hG-CSF (S) 
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4.2.2 Arabidopsis transformation and screening of Ri transformants 
For each construct or control (pBI121 vector only), ten Ro Arabidopsis plants 
ecotype Columbia-0 (Col-0) were transformed by Agrobacterium'mQdmtQd method 
through the process of vacuum infiltration (Bechtold et al,, 1993). After transformation, 
the plants were allowed to grow until they completed flowering. Then Ri seeds from all 
Ro plants were collected, surfaced-sterilized and plated on MS medium with kanamycin. 
Successfiil transformants (Ri plants), with the integrated of NPT II kanamycin resistant 
gene in the plant genome, were selected out as green plants while the non-transformants 
germinated but died eventually (Figure 4-10). 
講 推 胸 麵 
. . � . “ : ‘ ‘ ‘ 
Figure 4-10: Screening of successful Ri transformants 
Green Ri transformants were selected out on MS medium containing 
kanamycin while the non-transformants germinated but died eventually. 
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4.2.3 Screening of hemizygous transgenic Ri Arabidopsis 
Only parts of the transgenic Ri plants obtained in section 4.2.2 were hemizygous as 
the process of transgene integration into the plant genome during 
Agrobacterium-mQdLidiXQ& transformation is random. For screening of hemizygous 
transgenic Ri Arabidopsis, R2 seeds were surface-sterilized and plated on MS medium 
containing kanamycin. According to Mendelian law for monohybrid cross, those R2 
plants in each MS plate, giving 3 survival to 1 death ratio with acceptable Chi-square 
value, were the offsprings of a hemizygous transgenic Ri Arabidopsis (Figure 4-11)， 
and were selected to screen for homozygous transgenic R2 plants. Table 4-1 showed the 
results of Chi-square analysis of transgenic R2 plants to screen for hemizygous 
transgenic Ri Arabidopsis. 
_ 
) 
Figure 4-11: Screening of hemizygous transgenic Ri Arabidopsis 
R2 plants in this selection MS plate, giving 3 survival to 1 death ratio, 
were the offsprings of a hemizygous transgenic Ri Arabidopsis. 
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Table 4-1: Chi-square analysis of transgenic K2 Arabidopsis 
R2 plants, giving 3 survival to 1 death ratio (Chi-square value <3.84), 
were the offsprings of a hemizygous transgenic Ri Arabidopsis. 
No. Survived No. Died Chi-square Hemizygous 
Transgenic Ri plants 
(Rz plants) (R2 plants) value Ri plants 
Phas/His/EK/hG-CSF (H) 
H 1-1 44 15 0.01 + 
H 1-3 43 12 0.29 + 
H4-1 47 17 0.08 + 
H 4-2 57 7 6.75 -
H5-2 43 10 0.06 + 
H8-2 40 10 0.67 + 
H 10-1 46 16 0.03 + 
H 10-2 ^ ^ 12.8 -
Phas/SP/His/EK/hG-CSF (SH) 
SH 2-1 41 16 0.28 + 
SH 2-2 28 18 4.90 -
SH 3-1 38 20 2.79 + 
SH 4-1 34 19 3.33 + 
SH 5-1 42 14 0.00 + 
SH 6-1 52 10 2.60 + 
SH 7-1 38 23 5.25 -
SH 9-1 38 17 + 
Phas/SP/hG-CSF (S) 
S 1-1 26 15 2.93 + 
52-1 49 15 0.08 + 
S 2-2 54 5 8.59 -
53-1 47 16 0.01 + 
54-1 46 11 0.99 + 
S 5-3 68 12 6.40 -
S7-1 37 12 0.01 + 
S 8-1 50 1 14.4 -
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4.2.4 Screening of homozygous transgenic R2 Arabidopsis 
Two-third of the transgenic R2 plants in each selected plate obtained from section 
4.2.3 were hemizygous while one-third were homozygous. For screening of 
homozygous transgenic R2 Arabidopsis, about 50-100 R3 seeds from each R2 plants 
were surface-sterilized and plated on MS medium containing kanamycin. Finally, 
homozygous transgenic Ri Arabidopsis were selected out with all their offsprings R3 
plants survived in the selection medium (Figure 4-12). Table 4-2 showed the results of 
selected homozygous transgenic R2 Arabidopsis. 
I：〕以 J 一 ^ .J? ’ �； ‘ ‘ � 
I �* I ^  .〜.1 .’％,，�： 
Figure 4-12: Screening of homozygous transgenic R2 Arabidopsis 
Homozygous transgenic R2 Arabidopsis plants were selected out as all 
R3 plants survived in the selection MS plate. 
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Table 4-2: Results of selected homozygous transgenic R2 Arabidopsis 
Homozygous transgenic R2 Arabidopsis 
Phas/His/EK/hG-CSF (H) 
H 4-1 -2 , H 4 -1 -4 , H 4 - 1 - 7 
H 5 - 2 - 1 
H 10-1 -10 
Phas/SP/His/EK/hG-CSF (SH) 
S H 2 -1 -1 , S H 2-1-3，SH 2-1 -4 , S H 2 - 1 - 1 0 
S H 4 -1 -1 , S H 4 -1 -5 , S H 4 - 1 - 6 
S H 5 -1 -3 
S H 9-1-3，SH 9 -1 -4 , S H 9 -1 -9 , S H 9 - 1 - 1 0 
Phas/SP/hG-CSF (S) 
S 4 -1 -1 , S 4 - 1 - 4 
S 7 -1 -1 , S 7-1-2，S 7-1-4，S7-1-5, S 7 - 1 - 7 
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4.2.5 GUS assay 
Besides antibiotic (kanamycin) selection, GUS staining assay is also a preliminary 
and indirect method to indicate that the hG-CSF transgene was integrated into the 
genome of the transformants after vacuum infiltration, as hG-CSF chimeric gene was 
inserted between NPT II and GUS gene. Figure 4-13 showed the leaves of transgenic 
Arabidopsis were stained blue while the wild type leaf remained colorless upon GUS 
staining and after chlorophyll removal. 
^^ ^ I 
H l - l 4-1 5-2 10-1 躺 “ 
V' Wild type 
I 
,Transgene SH , , ^ • 
鄉-
r 
SH 2-1 3-1 5-1 9-1 
r 華 • • • 
S 1-1 2-1 3-1 4-1 
Figure 4-13: Gus staining of wild type and transgenic Arabidopsis 
Leaves of transgenic Arabidopsis were stained in blue color while the 
wild type leaf was colorless after GUS staining and chlorophyll removal. 
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4.2.6 Genomic DNA extraction 
Although transgenic Arabidopsis plant were selected out with the aid of antibiotic 
selection and GUS staining, it did not absolutely prove that hG-CSF transgene was 
integrated into the plant genome. Therefore, Southern blot analysis was carried out to 
further confirm the presence of transgene in the genome of transgenic plants. To do so, 
genomic DNA was first extracted from Arabidopsis leaves by using the CTAB protocol 
of Doyle et al. (1990). The DNA concentration was determined by OD260 measurement 
using a spectrophotometer and the quality of DNA was checked by gel electrophoresis 
(Figure 4-14). The results showed that genomic DNA was extracted successfully as 
desired bands of undigested genomic DNA with high molecular weight were seen in the 
gel. 
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Figure 4-14: Genomic DNA extracted from Arabidopsis leaves 
Undigested genomic DNA bands with high molecular weight were seen 
in the 1% agarose/TAE gel. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: Wild type control (Col-0) 
Lane 3: Transgene pBI 121 control 
Lane 4-10: Transgene Phas/His/EK/hG-CSF (H) 
(H 1-1, 1-3，4-1, 4-2, 5-2, 8-2，10-1) 
Lane 11-17: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2-1，3-1, 4-1, 5-1, 5-2, 6-1, 9-1) 
Lane 18-21: Transgene Phas/SP/hG-CSF (S) 
(S 2-1,3-1,4-1,7-1) 
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4.2.7 Southern blot analysis 
Besides antibiotic selection and GUS assay, Southern blot analysis was carried out 
to further confirm the integration of hG-CSF transgene in the genome of transgenic 
Arabidopsis. Genomic DNA (10)Lig) obtained in section 4.2.6 was first digested 
overnight with Hindlll and then separated by gel electrophoresis in a 0.8% agarose/TAE 
gel (Figure 4-15, upper panel). The digested DNA in the gel was then blotted onto a 
positively charged nylon membrane. Hybridization using a sense DIG-labeled DNA 
probe of the hG-CSF mature peptide sequence (Section 3.5.7) and detection with 
anti-DIG-AP was performed according to the method described in the DIG Nucleic 
Acid Detection Kit (Boehringer Mannheim). As shown in Figure 4-15 (lower panel), a 
genomic DNA fragment of expected size �3 k b was detected for all transgenic 
Arabidopsis while no hybridization signals were detected for the genomic DNA 
extracted from wild type and transgene pBI121 control. In addition, with the support of 
positive signal ( �3 k b ) given by positive control (plasmid harboring the chimeric gene 
construct), the signals detected in transgenic samples were not due to non-specific 
binding. Therefore, Southern blot analysis further confirmed that the hG-CSF transgene 
was successfully integrated into the genome of transgenic Arabidopsis. 
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Figure 4-15: Genomic DNA digestion and Southern blot analysis of transgenic 
Arabidopsis (H, SH, S) 
Genomic DNA (10|ig) was digested with HindlW and separated by gel 
electrophoresis (upper panel). The digested DNA in the gel was blotted 
onto a nylon membrane for hybridization and detection (lower panel). 
Lane 1: DNA molecular-weight marker III DIG-labeled 
(Boehringer Mannheim) 
Lane 2: +ve control (pBI/Phas/His/EK/hG-CSF, //mdlll digested - ISOpg) 
Lane 3-7: Transgene Phas/His/EK/hG-CSF (H) 
(H 1-1’ 4-1, 5-2, 8-2,10-1 
Lane 8: +ve control (pBI/Phas/SP/His/EK/hG-CSF, Hin&m digested - 150pg) 
Lane 9-13: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2-1, 4-1，5-1, 6-1, 9-1) 
Lane 14: +ve control (pBI/Phas/SP/hG-CSF, //mdlll digested - 150pg) 
Lane 15-18: Transgene Phas/SP/hG-CSF (S) 
(S 2-1，3-1，4-1, 7-1) 
Lane 19: Transgene pBI121 control 
Lane 20: Wild type control 
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4.2.8 Total RNA extraction from developing siliques 
After Southern blot analysis to confirm the integration of the transgene in the plant 
genome, the expression of transgene at mRNA level was examined by northern blot 
analysis. To do so, total RNA was first extracted from Arabidopsis developing siliques 
(�lOOmg) by using the method of Altenbach et al. (1989). The RNA concentration was 
determined by OD260 measurement using a spectrophotometer and the quality of RNA 
was checked by gel electrophoresis in a 1% agarose/formaldehyde gel (Figure 4-16, 
upper panel). The results showed that total RNA was successfully extracted without 
degradation and could be used for northern blot analysis. 
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4.2.9 Northern blot analysis 
Total silique RNA (10|Lig) was first separated by gel electrophoresis in a 1% 
agarose/formaldehyde gel (Figure 4-16, upper panel) and then transferred overnight to a 
positively charged nylon membrane using capillary transfer method. 
Hybridization with the anti-sense DIG-labeled DNA probe of the hG-CSF mature 
peptide sequence (Section 3.5.9) and detection using the anti-DIG-AP were preformed 
according to the method described in the DIG Nucleic Acid Detection Kit (Boehringer 
Mannheim). As shown in Figure 4-16 (lower panel), positive signals of expected size 
(-700 bases) were detected for most of the transgenic samples while no hybridization 
signal was detected in wild type and transgene pBI121 control. This indicated that 
transgenes were successfully expressed at transcriptional level in the seeds of transgenic 
Arabidopsis. 
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Figure 4-16: Northern blot analysis of total RNA from transgenic Arabidopsis 
Total silique RNA (10)ig) was first separated by gel electrophoresis 
(upper panel) and then the total RNA in the gel was blotted onto a nylon 
membrane for hybridization and detection (lower panel). 
Lane 1: 0.16-1.77kb RNA ladder (Gibco) 
Lane 2: Wild type control 
Lane 3: Transgene pBI 121 control 
Lane 4-5: Transgene Phas/His/EK/hG-CSF (H) 
(H 5-2-1, 10-1-10) 
Lane 6-8: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2-1-4, 5-1-3,9-1-4) 
Lane 9-10: Transgene Phas/SP/hG-CSF (S) 
(S 1-1-2，7-1-1) 
95 
4.2.10 Protein extraction and Tricine SDS-PAGE 
After northern blot analysis that confirm the expression of the hG-CSF mRNA, 
� 
further analysis should be performed to determine the expression of its corresponding 
protein. To achieve this，total seed protein was extracted from 0.05g of mature 
Arabidopsis seeds with 1ml protein extraction buffer and lOO i^g protein extract 
( � 5 jag/jil) was separated by 16.5% tricine-SDS-PAGE to examine whether a protein 
band representing the hG-CSF could be observed in the gel after electrophoresis and 
staining. Table 4-3 showed the expected size and storage location of the expressed 
hG-CSF in three different kinds of transgenic plants if transgenic expression is 
successful. As shown in Figure 4-17, no extra band with expected size (18 - 24kDa) was 
seen in all transgenic samples and it seemed no difference between the protein profiles 
of the wild type and transgenic samples neither. There were three possible reasons to 
explain this: 1) There was no expressed protein in the transgenic plants, 2) The protein 
expression level was too low to be observed, and 3) The expressed protein was masked 
by other plant proteins. 
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Table 4-3: The expected size and storage location of the expressed protein 
hG-CSF in transgenic plants 
Transgenic plants Expected protein size Expected storage location 
Cytosol 
Phas/His/EK/hG-CSF (H) 20.5kDa (with his-tag) ^ , 
of seeds 
23.7kDa (with his-tag + SP) Protein body 
Phas/SP/His/EK/hG-CSF (SH) ^ , 
21 .OkDa (with his-tag) of seeds 
21.3kDa (with SP) Protein body 
Phas/SP/hG-CSF (S) ^ , 
18.6kDa (No SP) of seeds 
參 The size of mature hG-CSF without 0-glycosylation = 18.6kDa 
參 The size of hG-CSF glycoprotein produced in human 
二 18.6kDa + IkDa (sugar chain) = 19.6kDa 
• The size of the sugar chain in the recombinant hG-CSF produced from transgenic 
plants cannot be estimated because the state of glycosylation varies between 
different organisms, different tissues and even different cells. 
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Figure 4-17: Tricine SDS-PAGE of Arabidopsis total seed protein (H, SH and S) 
Total seed protein extract (100|ig) was separated by tricine SDS-PAGE. 
Lane 1: BenchMark^^ Protein ladder (Gibco) 
Lane 2-3: Transgene Phas/His/EK/hG-CSF (H) 
(H 1-1,5-2) 
Lane 4-5: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2-1,9-1) 
Lane 6-7: Transgene Phas/SP/hG-CSF (S) 
(S 1-1, 7-1) 
Lane 8: Transgene pBI 121 control 
Lane 9: Wild type control 
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4,2.11 Western blot analysis 
There were three possible reasons to explain why no extra band was observed in 
the transgenic samples upon tricine SDS-PAGE as described in section 4.2.10. To find 
out the reason，western blot analysis was carried out. Total seed protein (100|ig) 
extracted from mature Arabidopsis seeds was separated by 16.5% tricine-SDS-PAGE. 
Then the protein in the tricine-gel was blotted onto PVDF membrane (Figure 4-18， 
upper panel). After electroblotting, the membrane was subjected to immunodetection 
using commercial available anti-hG-CSF polyclonal antibody (R&D Systems Inc.) 
(Figure 4-18, lower panel). The results showed that a desired protein band (�20kDa) 
was detected in all transgenic samples while no signals were detected in the wild type 
and transgene pBI121 controls. Therefore, western blot analysis confirmed that the 
hG-CSF transgene was successfully expressed at the translational level. 
However, by naked eye comparing the signal intensity of positive control 
(commercial non-glycosylated rhG-CSF produced by E.coli - PeproTech, USA) with 
those of transgenic samples, the level of rhG-CSF expression in the seeds of transgenic 
Arabidopsis was relatively low, about 0.02 - 0.05% of total seed protein extract. 
(For example, the signal intensity of transgene H5-2 was similar to that of positive 
control. Then the expression level of rhG-CSF in this transgenic plant can be calculated. 
20ng rhG-CSF/lOOjig STPE x 100% = 0.02% of STPE). For this reason, no obvious 
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bands could be seen in the gel after trincine SDS-PAGE and staining. However, this 
estimation method is preliminary and unreliable. Therefore, more accurate methods 
should be used such as laser densitometric scans of immunoblot and ELISA with a 
standard curve calibrated using known amounts of purified rhG-CSF. 
Besides, the results showed that the protein signals for transgene SH and S seemed 
to be stronger than that of transgene H. This may be due to the presence of phaseolin 
signal peptide in transgene SH and S, resulting in accumulation of target proteins in the 
protein bodies with stability. To further confirm the storage location of the recombinant 
proteins, immunogold labeling and electron microscopy can be carried out. 
On the other hand, the results showed that no difference was observed between the 
size of the non-glycosylated rhG-CSF (+ve control, 18.6kDa) and that of rhG-CSF from 
transgene S. However, no conclusion could be made whether partial or completed 
0-glycosylation occurred in the recombinant proteins because the size of the sugar 
chain in the rhG-CSF produced from transgenic plants cannot be estimated. The state of 
glycosylation varies between different organisms, different tissues and even different 
cells. 
Although the state of 0-glycosylation in the recombinant proteins remains unclear, 
the results of western blot analysis showed that the phaseolin signal peptide should be 




In addition, more bands were observed in samples from transgene SH. The high 
molecular weight band (40kDa) might likely be a hG-CSF dimer and the low bands 
(<18kDa) might be partial fragments of rhG-CSF due to genome rearrangement or 
protein degradation. 
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Figure 4-18: Western blot analysis oi Arabidopsis total seed protein (H, SH, S) 
Total seed protein extract (lOOpg) was separated by tricine SDS-PAGE 
and blotted onto PVDP membrane which were then stained with Ponceau 
S stain to confirm successful blotting (upper panel). Immunodetection 
was performed using anti-hG-CSF polyclonal antibody (lower panel). 
Lane 1: Rainbow marker (RPN 755) (Amersham) 
Lane 2-3: Transgene Phas/His/EK/hG-CSF (H) 
(H 1-1,5-2) 
Lane 4-5: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2-1,9-1) 
Lane 6-7: Transgene Phas/SP/hG-CSF (S) 
(S 1-1,7-1) 
Lane 8: +ve control (non-glycosylated rhG-CSF, 20ng) (PeproTech, USA) 
Lane 9: Transgene pBI 121 control 
Lane 10: Wild type control 
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4.2.12 Functional analysis 
Since hG-CSF was detected in the seeds of transgenic Arabidopsis by western blot 
analysis, it is very important to find out whether this newly expressed human protein in 
the transgenic plants still retains its biological activity as a cytokine. Therefore, a 
factor-dependent murine myeloblastic cell line NFS-60 was used in the functional 
analysis and a rapid colorimetric cell proliferation assay (MTT assay) was performed to 
determine the proliferation of NFS-60 cells induced by hG-CSF produced in transgenic 
Arabidopsis seeds. 
NFS-60 cells were thawed and cultured with every 2 - 3 day passage. When the 
cells were cultured in a healthy and normal state, MTT assay was performed and the 
intensity of purple color in each well of 96-well microplate was measured using 
Microplate Spectrophometer at OD570 (Table 4-4). At the same time, standard curve 
using purified rhG-CSF produced by E. coli (PeproTech, USA) was prepared (Graph 
4-2). Graph 4-1 showed that the hG-CSF produced in transgenic Arabidopsis seeds had 
in vitro biological activity to induce the proliferation of NFS-60 cells while wild type 
and transgene pBI121 control had no potential in stimulating cell proliferation. 
Moreover, the level of rhG-CSF produced in transgenic Arabidopsis seeds was about 
0.2 - 0.3% of the seed total protein extract (STPE). The result was derived from the 
standard curve calibrated using known amounts of purified rhG-CSF. [For example, 
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OD570 reading of transgene S7-1 (15|ag STPE/lml cell culture) was similar to that of 
purified rhG-CSF (50ng rhG-CSF/lml cell culture) in the standard curve. It means that 
there was 50ng rhG-CSF in 15|ig STPE. Therefore, the expression level of rhG-CSF in 
this transgenic plant can be calculated. 50ng rhG-CSF/15|ag STPE x 100% = 0.3% of 
STPE]. This level of expression is apparently higher than that determined by western 
blot and the result may be over estimated. This difference might be due to the high 
sensitivity of NFS-60 cell line towards rhG-CSF, the fitness of the cell line, and/or the 
actual biological activity of the commercial rhG-CSF used in standard curve. 
Besides, due to 10% of soluble proteins was extracted from Ig seeds [1ml STPE 
(~5|ig/|il) was obtained from 0.05g seeds, i.e. 5mg soluble proteins was extracted from 
0.05g seeds], the percentage of recombinant hG-CSF in transgenic Arabidopsis seeds 
was about 0.02 • 0.03% (i.e. 200 - 300|ag rhG-CSF / Ig seeds). 
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Table 4-4: OD570 measurements after MTT assay of transgenic Arabidopsis 
Standard curve 
(purified rhG-CSF from E. coli - PeproTech，USA)  
rhG-CSF concentration 、， Standard 
OD570 Mean • 
(ng/ml cell culture) derivation 
0 0.136 0.135 0.130 0.134 0.0026 
0 .05 0.173 0.169 0.174 0.172 0.0022 
0.5 0.241 0.229 0.239 0.236 0.0053 
5 0.334 0.327 0.356 0.339 0.0124 
10 0.442 0.403 0.396 0.414 0.0202 
50 0.489 0.489 0.488 0.488 0.0010 
100 0.486 0.507 0.498 0.497 0.0086 
3 0 0 0.535 0.516 0.491 0.514 0.0180 
Transgenic Arabidopsis 
(15|Lig seed total protein extract/ml cell culture)  
Transgenic ^ ^ ^^ Standard 
^ OD570 Mean . 
Arabidopsis derivation 
Transgene H 5-2 0.410 0.456 0.474 0.447 0.0270 
Transgene SH 9-1 0.439 0.456 0.451 0.449 0.0071 
Transgene S 7-1 0.468 0.515 0.470 0.484 0.0217 
Wild type 0.159 0.158 0.157 0.158 0.0008 
pBI121 control 0.161 0.156 0.153 0.157 0.0033 
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Graph 4-1: Biological activity of rhG-CSF produced in transgenic Arabidopsis 
seeds 
Seed total protein extract (3|ig) in lOOjil RPMI-1640 medium was added 
to lOOjal of NFS-60 cells for MTT assay and by comparing to standard 
curve, the level of rhG-CSF protein in transgenic Arabidopsis seeds was 
about 0.2 - 0.3% of the seed total protein extract. 
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Graph 4-2: Growth curve of NFS-60 cells to rhG-CSF (Standard curve) 
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4.3 Expression in tobacco 
4.3.1 Agrobacterium LBA4404/pAL4404 transformation 
By electroporation，Agrobacterium LBA4404/pAL4404 was transformed with 
either one of the three chimeric gene constructs (H, SH and S) made in section 4.1.4. 
The plasmid DNAs, isolated from the transformed Agrobacterium, were digested with 
Hindlll to confirm successful Agrobacterium transformation. As described in section 
4.1.4，two fragments, 15kb and 3kb，were formed after Hindlll digestion. The results 
showed that the Agrobacterium transformation was successful (Figure 4-19) and the 
transformed Agrobacterium LBA4404 were ready for tobacco transformation. 
1 2 3 4 
15kb 
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Figure 4-19: Gel electrophoresis of plasmid DNAs from transformed 
Agrobacterium LBA4404/pAL4404 after digestion with Hindlll 
Two desired bands (15kb and 3kb) were seen in the gel. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: pBI/Phas/His/EK/hG-CSF (H) 
Lane 3: pBI/Phas/SP/His/EK/hG-CSF (SH) 
Lane 4: pBI/Phas/SP/hG-CSF (S) 
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4.3.2 Tobacco transformation and regeneration of transformants 
Tobacco transformation was performed using the method of Fisher et al (1995). 
The leaf-discs, cut from one-month-old tobacco, were immersed in transformed 
Agrobacterium culture for 10 minutes and then transferred to co-cultivation medium for 
2 days. After co-cultivation, the leaf-discs were transferred onto selection shooting 
medium containing kanamycin for callus and shoot formation. After 2 - 3 weeks, calli 
were formed from the transformed tobacco cells of the leaf-discs and regenerated shoots 
appeared after 2 more weeks. Then the regenerated shoots were cut off and transferred 
to selection rooting medium for root formation. After 3 - 4 weeks, the regenerated 
transgenic tobacco were transferred to soil and grown in greenhouse for further 
expression analysis (Figure 4-20). 
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Figure 4-20: Regeneration of transgenic tobacco 
After co-cultivation, leaf-discs were transferred onto selection shooting 
medium. After 2 weeks, calli from transformed tobacco cells were 
formed (A) and shoots were regenerated after 2 more weeks (B). Then 
the shoots were cut and transferred to selection rooting medium for 
rooting (C). Finally, the regenerated transgenic tobacco were transferred 
to soil and allowed to grow in green house for further analysis (D). 
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4.3.3 GUS assay 
Besides antibiotic (kanamycin) selection, GUS staining assay is also a preliminary 
and indirect method to indicate whether the hG-CSF transgene was integrated into the 
genome of the transgenic tobacco. Figure 4-21 showed the leaves of transgenic tobacco 
were stained blue while the wild type leaf remained colorless after GUS staining and 
chlorophyll removal. 
Transgene Transgene Transgene 
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Figure 4-21: Gus staining of wild type and transgenic tobacco 
Leaves of transgenic tobacco were stained blue while the wild type leaf 
was colorless after GUS staining and chlorophyll removal. 
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4.3.4 Genomic DNA extraction 
Besides antibiotic selection and GUS staining, Southern blot analysis was carried 
out to further confirm the presence of transgene in the genome of transgenic tobacco. To 
do so, genomic DNA was first extracted from tobacco leaves using the CTAB protocol. 
The DNA concentration was determined by OD260 and the quality of DNA was checked 
by gel electrophoresis (Figure 4-22). The results showed that high molecular weight 
genomic DNA was successfully extracted. 
112 
H SH S 
1 2 3 4 5 6 7 8 9 10 11 12 
(kb) 
2.0 
Figure 4-22: Genomic DNA extracted from tobacco leaves 
Undigested genomic DNA with high molecular weight were seen in the 
1% agarose/TAE gel. 
Lane 1: Ikb plus marker (Gibco) 
Lane 2: Wild type control (Col-0) 
Lane 3: Transgene pBI121 control 
Lane 4-6: Transgene Phas/His/EK/hG-CSF (H) 
(H3, 10, 15) 
Lane 7-9: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2，7，8) 
Lane 10-12: Transgene Phas/SP/hG-CSF (S) 
(S 4，12, 14) 
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4.3.5 Southern blot analysis 
Genomic DNA (20|ig) was first digested overnight with Hindlll and then separated 
by gel electrophoresis in a 0.8% agarose/TAE gel (Figure 4-23, upper panel). The 
digested DNA in the gel was then blotted onto a positively charged nylon membrane. 
Hybridization using a sense DIG-labeled DNA probe of the hG-CSF mature peptide 
sequence (Section 3.5.7) and detection with anti-DIG-AP was performed. As shown in 
Figure 4-23 (lower panel), a genomic DNA fragment of expected size ( �3 k b ) was 
detected for all transgenic tobacco while no hybridization signals were detected for the 
genomic DNA extracted from wild type and transgene pBI121 control. In addition, with 
the support of positive signal ( �3 k b ) given by positive control, the signals detected in 
transgenic samples were not due to non-specific binding. Therefore, Southern blot 
analysis further confirmed that the hG-CSF transgene was successfully integrated into 
the genome of transgenic tobacco. 
114 
H SH S 
WT pBI +ve +ve 




Figure 4-23: Genomic DNA digestion and Southern blot analysis of transgenic 
tobacco (H，SH, S) 
Genomic DNA (20^g) was digested with Hindlll and separated by gel 
electrophoresis (upper panel). The digested DNA in the gel was blotted 
onto a nylon membrane for hybridization and detection (lower panel). 
Lane 1: Wild type control 
Lane 2: Transgene pBI121 control 
Lane 3-5: Transgene Phas/His/EK/hG-CSF (H) 
(H 3，10，15) 
Lane 6-8: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2, 7, 8) 
Lane 9-11: Transgene Phas/SP/hG-CSF (S) 
(S 4，12，14) 
Lane 12-13: +ve control (pBI/Phas/His/EK/hG-CSF, HMIII digested) 
(15pg for lane 12，150pg for lane 13) 
Lane 14: DNA molecular-weight marker III DIG-labeled 
(Boehringer Mannheim) 
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4.3.6 Total RNA extraction from immature seeds 
Total RNA was extracted from tobacco immature seeds (18 - 20 day after 
flowering) using the method of Altenbach et al, (1989). The RNA concentration was 
determined by OD260 measurement and the quality of RNA was checked by gel 
electrophoresis in a 1% agarose/formaldehyde gel (Figure 4-24，upper panel). The 
results showed that total RNA was successfully extracted from tobacco immature seeds 
without degradation and could be used for northern blot analysis. 
4.3.7 Northern blot analysis 
Total seed RNA (lOpg) was first separated by gel electrophoresis in a 1% 
agarose/formaldehyde gel (Figure 4-24, upper panel) and then transferred to a positively 
charged nylon membrane. Hybridization with the anti-sense DIG-labeled DNA probe of 
the hG-CSF mature peptide sequence (Section 3.5.9) and detection using the 
anti-DIG-AP were preformed. As shown in Figure 4-24 (lower panel). The results 
showed that positive signals (-700 bases) were detected for most of the transgenic 
samples while no hybridization signal was detected in wild type and transgene pBI121 
control. This indicated that transgenes were successfully expressed at transcriptional 
level in the seeds of transgenic tobacco. 
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Figure 4-24: Northern blot analysis of total seed RNA from transgenic tobacco 
Total silique RNA (10|ag) was first separated by gel electrophoresis 
(upper panel) and then the total RNA in the gel was blotted onto a nylon 
membrane for hybridization and detection (lower panel). 
Lane 1: 0.16-1.77kb RNA ladder (Gibco) 
Lane 2: Wild type control 
Lane 3: Transgene pBI121 control 
Lane 4-7: Transgene Phas/His/EK/hG-CSF (H) 
(HIO, 15, 17, 25) 
Lane 8-12: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 2, 7, 14, 15，17) 
Lane 13-14: Transgene Phas/SP/hG-CSF (S) 
(S 4, 12) 
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4.3.8 Protein extraction and Tricine SDS-PAGE 
To determine the expression of transgene at the translational level, total seed 
protein was extracted from O.lg of mature tobacco seeds with 1ml protein extraction 
buffer and lOOjag protein extract was separated by 16.5% tricine-SDS-PAGE. Similar to 
the results described for Arabidopsis in section 4.2.10, no extra band with expected size 
was seen in all transgenic samples and there seemed no difference between the protein 
profile of the wild type and transgenic samples (Figure 4-25). The possible reasons are 
similar to those as described in section 4.2.10. 
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Figure 4-25: Tricine SDS-PAGE of tobacco total seed protein (H, SH, S) 
Total seed protein extract (100|ig) was separated by tricine SDS-PAGE. 
Lane 1: BenchMark™ Protein ladder (Gibco) 
Lane 2-3: Transgene Phas/His/EK/hG-CSF (H) 
(H 17, 25) 
Lane 4-5: Transgene Phas/SP/His/EK/hG-CSF (SH) 
(SH 7, 8) 
Lane 6-7: Transgene Phas/SP/hG-CSF (S) 
(S 4,12) 
Lane 8: Transgene pBI 121 control 
Lane 9: Wild type control 
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4,3.9 Western blot analysis 
As described in section 4.2.10, there were several possible reasons to explain 
why no extra band was observed in the transgenic samples upon tricine SDS-PAGE. To 
find out the reason, western blot analysis was carried out. Seed total protein extract 
(lOOng) was separated by tricine-SDS-PAGE and then blotted onto PVDF membrane 
(Figure 4-26, upper panel). After electroblotting, the membrane was subjected to 
immunodetection using anti-hG-CSF polyclonal antibody (R&D Systems Inc.) (Figure 
4-26, lower panel). The results showed that a desired protein band was detected in all 
transgenic samples (except SH 7) while no signals were detected in wild type and 
transgene pBI121 control. Therefore, western blot analysis confirmed the successful 
expression of hG-CSF transgene at translational level for the transgenic tobacco. 
However, similar to the results of Arabidopsis, the expression level of the target protein 
was too low to be observed in the stained gel after tricine SDS-PAGE. The levels of 
rhG-CSF produced in transgenic tobacco seeds were estimated to be about 0.01% -
0.03% of seed total protein extract using the method as described in section 4.2.11. 
However, this estimation method is preliminary and unreliable. Therefore, more 
accurate methods should be used such as laser densitometric scans of immunoblot and 
ELISA with a standard curve calibrated using known amounts of purified rhG-CSF. 
Besides, the results showed that the signals for transgene SH and S seemed to be 
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stronger than that of transgene H and the possible reason was suggested as in the case of 
transgenic Arabidopsis. To further confirm the storage location of the recombinant 
proteins, immunogold labeling and electron microscopy can be carried out. 
Moreover, the size of rhG-CSF from transgene S (18.6kDa) was similar to that of 
positive control. However, no conclusion could be made whether partial or completed 
0-glycosylation occurred in the recombinant proteins as described in section 4.2.11. 
Finally, similar to the case in transgenic Arabidopsis, phaseolin signal peptide appeared 
to be removed from the mature rhG-CSF as the size of recombinant protein from 
transgene S was reduced from 21.3kDa to 18.6kDa. 
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Figure 4-26: Western blot analysis of tobacco total seed protein (H, SH, S) 
Total seed protein (100|ag) was separated by tricine SDS-PAGE and 
blotted onto PVDP membrane which were then stained with Ponceau S 
stain to confirm successful blotting (upper panel). Immunodetection was 
performed using anti-hG-CSF polyclonal antibody (lower panel). 
Lane 1: Rainbow marker (RPN 755) (Amersham) 
Lane 2: +ve control (non-glycosylated rhG-CSF, 20ng) (PeproTech, USA) 
Lane 3-4: Transgene Phas/SP/hG-CSF (S) 
(S 4 , 1 2 ) 
Lane 5-6: Transgene Phas/SP/His/EK/hG-CSF (H) 
(H 17, 25) 
Lane 7: Transgene Phas/His/EK/hG-CSF (SH 7) 
Lane 8: Transgene pBI 121 control 
Lane 9: Transgene Phas/His/EK/hG-CSF (SH 8) 
Lane 10: Wild type control 
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4.3.10 Functional analysis 
By western blot analysis, hG-CSF was detected in the seeds of transgenic tobacco. 
Therefore, functional analysis was carried out to check the biological activity of the 
protein. A factor-dependent murine myeloblastic cell line NFS-60 was used in the 
functional analysis and MTT assay was performed to determine the proliferation of 
NFS-60 cells as induced by the hG-CSF produced in transgenic tobacco seeds. 
Since the functional analysis of hG-CSF produced in tobacco was performed 
together with that of Arabidopsis, the reading of ODsyoand graph of the standard curve 
were shared (Table 4-4 and Graph 4-2), As shown in Table 4-5 and Graph 4-3，hG-CSF 
produced in transgenic tobacco seeds showed in vitro biological activity to induce the 
proliferation of NFS-60 cells while wild type and transgene pBI121 control had no 
potential of stimulating the cell proliferation. Moreover, the level of rhG-CSF produced 
in transgenic tobacco seeds was about 0.05% - 0.2% of the seed total protein extract by 
comparing to the standard curve as described in section 4.2.12. This apparent higher 
expression level as compared to that in western blot might be due to the possible 
reasons as described in section 4.2.12. 
Besides, due to only 5% of STPE was extracted from Ig tobacco seeds (lower than 
that from Arabidopsis seeds), the percentage of recombinant hG-CSF in transgenic 
tobacco seeds was about 0.0025 - 0.01% (i.e. 25 - lOOjig hG-CSF / Ig seeds). 
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Table 4-5: OD570 measurements after MTT assay for transgenic tobacco 
Standard curve 
(purified rhG-CSF from E. coli - PeproTech, USA)  
rhG-CSF concentration _ _ 、， Standard 
OD570 Mean . 
(ng/ml cell culture) derivation 
0 0.136 0.135 0.130 0.134 0.0026 
0 .05 0.173 0.169 0.174 0.172 0.0022 
0.5 0.241 0.229 0.239 0.236 0.0053 
5 0.334 0.327 0.356 0.339 0.0124 
10 0.442 0.403 0.396 0.414 0.0202 
50 0.489 0.489 0.488 0.488 0.0010 
100 0.486 0.507 0.498 0.497 0.0086 
3 0 0 0.535 0.516 0.491 0.514 0.0180 
Transgenic tobacco 
(15|ig seed total protein extract/ml cell culture)  
Transgenic ^ ^ , , Standard 
^ OD570 Mean • 
tobacco derivation 
Transgene H17 0.387 0.376 0.462 0.408 0.0382 
Transgene SH 8 0.516 0.403 0.455 0.458 0.0462 
Transgene S 12 0.478 0.448 0.450 0.459 0.0137 
Wild type 0.147 0.124 0.158 0.143 0.0142 
pBI121 control 0.152 0.147 0.153 0.151 0.0026 
124 
Biological activity of rhG-CSF produced 
in transgenic tobacco seeds 
45 ？'"II"/"I.'I•； 1,-,‘-:八|| •^•：”:ii-1|"' I I ？ � 1 1 1 . 1. - •~pr--- ""•I 
麵___麵鎮_•插•尋越酵爾麵鍵 
40【：： j m WM 
35 _ 二 ： ： • • 
？ 20 ‘ • M ；； — ？ 
：、 ‘““ 1 1 • • 
1； 7 WMi—a HHHHH ‘ (！ 
10 口 、 ^ ： ” ： ： … ， . … / : ： 丨 \ 
Q I:..…/iml�- • . l^Bl ‘“： l i i in ‘ ‘： ..秘 
Transgene Transgene Transgene Wild pBI121 
H SH S type control 
Graph 4-3: Biological activity of rhG-CSF produced in transgenic tobacco seeds 
Seed total protein extract (3|ig) in 100|il RPMI-1640 medium was added 
to lOOfil of NFS-60 cells for MTT assay and by comparing to standard 
curve, the level of rhG-CSF protein in transgenic tobacco seeds was 
about 0.05 - 0.02% of the seed total protein extract. 
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Chapter 5: Discussion 
5.1 Introduction 
Human granulocyte colony-stimulating factor (hG-CSF) is one kind of cytokine 
and plays an important role in hematopoiesis especially in neutrophil lineage. In daily 
life, sufficient amounts of hG-CSF are produced by primary bone marrow stromal cells, 
macrophages, fibroblasts and endothelial cells to maintain the basal level of neutrophils 
in our body. However, upon various kinds of stimulations such as bacterial and fungal 
infections, the cells are induced to produce more amounts of hG-CSF which increase 
the neutrophil level and in turn protect our body from various infections. Therefore, 
hG-CSF is very useful in clinical applications and is especially used for neutropenia 
treatment. Since neutropenia is commonly related to chemotherapy, radiotherapy, bone 
marrow transplantation, acute leukemia, AIDS and other diseases, there is a very high 
demand of hG-CSF in clinical applications all over the world. Besides, hG-CSF therapy 
can in turn reduce the days of hospitalization and antibiotic requirements with 
subsequent cost benefits to hospitals and patients. Therefore, hG-CSF is of very high 
economic value and thus recombinant hG-CSF has been mass-produced in different 
kinds of expression systems such as bacteria, yeasts, animal cell lines and transgenic 
animals for basic research and clinical application. 
On the other hand, due to the rapid development of plant and molecular 
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biotechnology, transgenic plants have become a promising production system of 
recombinant proteins. Although no reports demonstrated that recombinant hG-CSF was 
produced in transgenic plants, two significant human hematopoietic growth factors, 
GM-CSF and Epo, have been successfully produced in the plant system and the results 
showed that both recombinant proteins had in vitro biological activities. However, due 
to the hematopoietic growth factors are glycoproteins and the glycosylation of plants 
and mammalians are different from each other in some aspects, the in vivo stability and 
biological activity of recombinant hematopoietic growth factors produced in transgenic 
plants may be affected. The above two examples also indicated that glycosylation may 
be a problem for the use of transgenic plants to produce recombinant human GM-CSF 
and Epo with high stability. Therefore, consideration should be taken when one wants to 
use plants as bioreactors to produce glycoprotiens in which glycosylation is an 
important element for their stability and biological activity. However, it is not a problem 
in the case of hG-CSF as this glycoprotein only possesses 0-glycosylation which shows 
no significant functions to the protein. Moreover, non-glycosylated recombinant 
hG-CSF produced in bacteria has similar in vivo stability and biological activity to those 
of the native glycosylated hG-CSF and widely used in clinical applications as filgrastim. 
As a result，it is worth to using plants as bioreactors to produce these valuable 
recombinant proteins at a lower production cost than the other expression systems. 
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5.2 Successful in producing biologically active rhG-CSF from 
transgenic plants 
In this study, two model plants, Arabidopsis and tobacco, were selected to test 
whether recombinant hG-CSF could be produced in both transgenic plants. Three 
hG-CSF chimeric gene constructs were made under the control of seed-specific 
phaseolin promoter from French bean and then used to transform Arabidopsis and 
tobacco using Agrobacteriuni'mQ&idiXQd transformation. Both transgenic plants were 
identified and the expressions of the hG-CSF chimeric genes were assayed. GUS 
staining and Southern blot analysis showed that the chimeric genes were successfully 
integrated into the genome of transgenic Arabidopsis and tobacco. Moreover, successful 
expressions of the hG-CSF transgene at transcriptional level in both transgenic plants 
were confirmed by northern blot analysis. 
Tricine SDS-PAGE indicated that the protein profiles of the native and both 
transgenic plants displayed similar patterns and no extra band with expected size was 
seen in all transgenic samples, suggesting that rhG-CSF was not produced in the 
transgenic plants, or the protein expression level was too low to be observed in the gel, 
or the expressed protein was masked by other plant proteins. 
The possible reasons were investigated by western blot analysis. The results 
showed that a desired protein band was detected in all transgenic samples while no 
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signals were detected in wild type and transgene pBI121 control. Therefore, western 
blot analysis confirmed the successful expressions of hG-CSF transgene at translational 
level in both transgenic plants. 
5.2.1 Production level 
By naked eye comparing the signal intensity of positive control (commercial 
non-glycosylated rhG-CSF produced by E.coli - PeproTech, USA) with those of 
transgenic samples on the immunoblot, the expression levels of rhG-CSF in the seeds of 
transgenic Arabidopsis and tobacco were estimated as 0.02 一 0.05% and 0.01 - 0.03% 
of total seed protein extract, respectively. The expression levels of rhG-CSF in both 
transgenic plants were low so that no obvious bands could be seen in the protein gel. 
However, this estimation method is preliminary and unreliable. Therefore, more 
accurate methods should be used such as laser densitometric scans of immunoblot and 
ELISA with a standard curve calibrated using known amounts of purified rhG-CSF. 
On the other hand, functional assay was performed and the results showed that the 
expression levels of rhG-CSF in the seeds of transgenic Arabidopsis and tobacco were 
estimated as 0.2 - 0.3% and 0.05 一 0.2% of total seed protein extract, respectively. The 
expression levels were apparently higher than that estimated by western blot and the 
result may be over estimated. This difference might be due to the high sensitivity of 
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NFS-60 cell line towards rhG-CSF, the fitness of the cell line, and/or the actual 
biological activity of the commercial rhG-CSF used in the standard curve. 
Although the expression levels of rhG-CSF in both transgenic plants estimated 
from western blot and functional assay were preliminary and not compatible, the data 
could roughly show that the expression level of rhG-CSF in transgenic plants was not 
very low or very high. The approximate range of production yield was from the lowest 
estimated value 0.01% to the highest one 0.3%. 
5.2.2 O-glycosylation 
The results showed that no difference was observed between the size of the 
non-glycosylated rhG-CSF (+ve control, 18.6kDa) and that of rhG-CSF from transgene 
S. However, no conclusion could be made whether partial or completed O-glycosylation 
occurred in the recombinant proteins because the size of the sugar chain in the rhG-CSF 
produced from transgenic plants cannot be estimated. The state of glycosylation varies 
between different organisms, different tissues and even different cells. 
Although the O-glycosylation state of rhG-CSF produced in transgenic plants 
remains unclear, it is not a problem as O-glycosylation of hG-CSF is not an essential 
element for its stability and biological activity. In addition, as mentioned before, 
non-glycosylated rhG-CSF produced in bacteria has similar stability and activity to the 
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native glycosylated one and is widely used in clinics. 
5.2.3 Phaseolin signal peptide 
The results of western blot analysis showed that the phaseolin signal peptide 
should be removed from rhG-CSF of transgene S as the size of this protein was reduced 
from 21.3kDa to 18.6kDa. To further confirm the storage location of the recombinant 
hG-CSF with or without phaseolin signal peptide, immunogold labeling and electron 
microscopy can be carried out. 
5.2.4 Functional analysis 
Finally, murine myeloblastic cell line NFS-60 was set up and the in vitro biological 
activity of rhG-CSF produced in the seeds of both transgenic plants was determined in a 
cell proliferation assay (MTT assay). The results showed that rhG-CSF produced in 
transgenic Arabidopsis and tobacco seeds had in vitro biological activity to induce the 
proliferation of NFS-60 cells while wild type and transgene pBI121 control had no 
potential to stimulate the cell proliferation. 
Therefore, biologically active rhG-CSF produced in transgenic plant seeds has 
promising potential to be used in clinical applications. Due to the expression level of 
rhG-CSF produced in transgenic plants was 0.01 — 0.3% of seed total protein extract as 
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described in section 5.2.1 and � 1 0 % of STPE could be extracted from transgenic seeds, 
the percentage of rhG-CSF in transgenic Arabidopsis seeds was about 0.001 - 0.03% 
(i.e. 10 - 300|ig rhG-CSF / Ig seeds). According to section 2.1.5，the median dose of 
rhG-CSF applied to patients is 5 fag/kg/day so that a male patient (�60kg) needs to take 
300|ig rhG-CSF for one day. It means that 1 - 30g transgenic seeds are required by the 
patient to take enough rhG-CSF for one day and this amount of transgenic seeds 
required is acceptable and possible in clinical applications. 
5.3 Comparison of the productivity of other expression systems 
producing rhG-CSF 
According to Pen (1996), levels of recombinant proteins produced are difficult to 
compare between different expression systems because it is very difficult to give 
accurate estimates of average and maximum production levels achieved by the various 
systems, and many companies usually refuse to report the industrially achieved levels 
for commercial reasons. As a result, accurate comparison of the productivity of 
expression systems producing rhG-CSF would not be available here and only a brief 
comparison could be achieved. 
The data (Table 5-1) showed that the expression level of rhG-CSF produced in 
transgenic plants (0.01 - 0.3% of total soluble proteins) should be much lower than that 
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of bacteria (up to 20% of total soluble proteins) while it is difficult to compare with 
yeast and animal cell line because the ratio used as a measure of the expression level is 
different from each other. Although the level of rhG-CSF produced in transgenic plants 
is lower than that in bacteria, using plants as bioreactors to produce rhG-CSF is an 
attractive and cost-effective alternative to other expression systems because the 
production cost of plant system is much lower than that of fermentation-based systems. 
Moreover, plants are free from human pathogens and the recombinant proteins can be 
stored in seeds for a long time. Moreover, the very high feasibility of technological 
improvements in transgenic plants, compared to the traditional fermentation-based 
production system, can allow these novel plant bioreactors to reach the market place. 
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Table 5-1: Comparison of the productivity of other expression systems 
producing rhG-CSF 
Expression Expression level of _ ^ 
Pros Cons ^^ References 
system rhG-CSF  
-High yield - Production of - 10% of total cellular -Komatsu et al 
-Inexpensive insoluble aggregates proteins 1987 
-No post-translational - 500mg/ L culture -Kang et al 1995 
modification - 1.7g/ L culture -Chung et al 1998 
-Refolding is required - 20% of total proteins -Jeong and Lee 
2001 
-Inexpensive - Relatively low yield - 60mg/ L culture -Yang et al 1997 
-Post-translational - Low secretion 
Yeast modification efficiency 
-Hyperglycosylation 
-most similar to native - Relatively low yield - 10 to 40mg/ L culture -Kubota et al 1990 
proteins - Expensive 
Animal 
-Post-translational - Contamination of 
cell line 
modification human pathogens 
-Lower production - Relatively low yield - 0.01 to 0.3% of seed  
cost than fermentation - Cost of purification total protein extract 
based systems may be high (Refer to section 5.2.1) 
-Post-translational 
modification 
-No contamination of 
Plant , , 
human pathogens 
-Recombinant proteins 
can be produced in 
seeds with high 
stability and indefinite 
storage period  
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5.4 Comparison of the productivity of plants producing different 
human proteins 
Although the expression level of rhG-CSF in transgenic plants is lower than that of 
other expression systems, the productivity of plants transgenic for hG-CSF is much 
better than that of many transgenic plants that produce other kinds of human proteins 
such as Epo, interferon-P, protein C, GM-CSF, serum albumin and GAD-65. On the 
other hand, some transgenic plants can produce higher levels of recombinant human 
proteins such as insulin (0.5 - 1.0% of total soluble proteins) and enkephalins (2.9% of 
TSP) (Table 5-2). 
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Table 5-2: Comparison of the productivity of plants producing different human proteins 
Recombinant Transgenic Expression level 
Promoter � ， i h . � References 
human protein plant (% of total soluble proteins)  
- He et al 
Epo Tomato 35S Pro 4 X lO"^  % 19卯 
. Matsumoto et al 
Epo Tobacco 35S Pro 2.6 X10"^ % 199^ 
. Edelbaum et al 
Interferon-P Tobacco 35S Pro 1.7 X10"^ % 199^ 
Carmer et al 
Protein C Tobacco 35S Pro 0.001 % 
1996 
Rice glutelin … n , Ganz et al 
GM-CSF Tobacco ^ � 3 Pro 0.01% 1995 
Sijmons et al 
Serum albumin Tobacco 35S Pro 0.02 % 199� 
Porceddu et al 
GAD-65 Tobacco —— 0.01-0.04% 例^  
G-CSF Arabidopsis phaseolin Pro 0.01 - 0.3 % —— 
Tobacco  
Ma et al 
GAD-67 Tobacco - - 0.4 % ^000 
Korea-Inst. Sci. 
Insulin Tobacco 35S Pro 0.5 - 1 . 0 % Technol. 1991 
Vandekerckhove 
Enkephalins Oilseed Gt3 Pro 2.9% etal\9^9  
I I I — — 
* GAD - Glutamic acid-decarboxylase has two isoforms: GAD-65 and GAD-67 
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5.5 Future perspectives 
In this study, successful production of biologically active rhG-CSF in transgenic 
Arabidopsis and tobacco seeds were achieved. This promising result suggested that 
seeds could be used as bioreactors to produce this valuable hematopoietic growth factor 
for clinical applications. However, the expression level of this protein in transgenic 
plants is low and it is not efficient for mass production. Therefore, increasing 
production yield and developing an efficient purification process is necessary in the 
future. We can increase the yield by expressing the recombinant proteins in food crops 
such as soybean, potato and maize with other strong and organ-specific promoters. For 
efficient and simple purification process, oleosin-fusion technology, which allows 
extraction with oil bodies, can be applied. 
On the other hand, in vivo bioassay should be carried out to test the biological 
activity and stability of rhG-CSF produced from transgenic plants in the bodies of 
animals by injection of rhG-CSF into the animals such as mice and observing the 
changes of the neutrophil amount over the time. Besides, we can try to feed the animals 
with transgenic seeds to see whether rhG-CSF could take out its action in neutrophil 
lineage after ingestion. If yes, purification of rhG-CSF from plant materials is 
unnecessary and the cost of downstream process decreases significantly with 
subsequent cost benefits to both hospitals and patients. 
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Chapter 6: Conclusion 
In this study, three chimeric genes containing the human granulocyte 
colony-stimulating factor (hG-CSF) cDNAs under the regulation of the strong and 
seed-specific phaseolin promoter were used to transform Arabidopsis and tobacco. After 
Agrobacterium-mQ^miQd transformation, transgenic plants were identified for both 
Arabidopsis and tobacco by kanamycin selection. GUS staining assay and Southern blot 
analysis confirmed that the transgenes were integrated into the plant genomes. 
Successful expressions of the hG-CSF cDNAs at transcriptional level were detected in 
both transgenic plants by northern blot analysis. Finally, western blot analysis 
demonstrated that recombinant hG-CSF could be produced in the seeds of transgenic 
Arabidopsis and tobacco. Functional assay indicated that these recombinant proteins 
had in vitro biological activity by stimulating the proliferation of murine myeloblastic 
cell line NFS-60. 
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